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SUMMARY 
Bronchiolitis obliterans syndrome (BOS) is a major chronic complication after lung 
transplantation (LTx). BOS is characterized by massive fibrosis in areas surrounding small 
airways that leads to air trapping induced pulmonary dysfunction. Several cellular and 
molecular features of BOS have been described in the latest stage of the disease, however, 
triggers that promote airway fibroproliferation and the disease-progression have not yet been 
sufficiently investigated.  
Cathepsin-B (CatB), a lysosomal cysteine-protease, is able to exert its activity under acidic and 
neutral pH conditions, cleaving its targets intracellularly and extracellularly. CatB has been 
described in association with several fibrotic diseases and was shown to enforce fibrotic 
pathways in vitro conditions. Furthermore, the relevance of CatB in BOS progression has not 
yet been investigated.  
In this study, we aimed to elucidate the role of CatB as potential trigger of BOS pathogenesis 
and its contribution to the progression of the disease. 
CatB expression and its activity in lung tissue and bronchoalveolar lavage fluid (BALF) were 
determined using Western blotting, staining and a FRET-based activity assay, respectively. 
Pro-collagen levels were analysed in BALF samples via ELISA. To further investigate the 
impact of Cathepsin-B in the pathophysiology of BOS, we used an in vivo orthotopic left-lung 
transplantation mouse model of early-stage of BOS development, called lymphocytic 
bronchiolitis (LB). Mechanistical studies were performed in vitro using macrophage and 
fibroblast cell lines. 
With our study, we demonstrated that CatB protein levels were increased in BALF samples 
and in lung tissue of patients who developed BOS, as well as in our murine model of LB. 
Interestingly, CatB activity was increased in BALF from BOS patients, already at early stages 
of the disease. Remarkably, the activity of CatB negatively correlated with the lung function 
over the progression of BOS disease, and was associated with an increased biosynthesis of pro-
collagen. We furthermore identified infiltrating pro-inflammatory macrophages being the main 
source of CatB in BOS. Mechanistically, we demonstrated that CatB contributed to TGF-β1-
dependent activation of fibroblasts, and its inhibition prevented BOS phenotype.  
In conclusion, infiltrating macrophages, in areas surrounding airways, release CatB that 
promotes fibroblast-activation and subsequent collagen deposition, driving BOS progression. 
CatB may represent a potential therapeutic target to prevent BOS progression. 
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1. INTRODUCTION 
 
1.1 Lung Transplantation 
 
The lung, differently from other organs, is constantly exposed to external and internal insults, 
and must handle air pollution particles, bacteria, virus, gastro-intestinal reflux/aspiration, but 
also immunological factors that are released from the immune system after tissue-injury (1). 
Despite high dosage of immunosuppressants, the organ can be recognised as foreign, and donor 
molecules are presented as antigen by innate immune cells to the adaptative immune system, 
causing the release of donor specific antibodies (DSAs) (2). DSA are known to be risk factors 
of organ failure (3-4). Patients affected by long-term lung disease rely on lung transplantation 
(LTx) as the only therapeutic intervention for a longer survival (5). Depending on the 
underlying disease, patients may require single or double LTx. During LTx, a diseased or 
failing lung is replaced by a healthy lung (Figure 1), usually derived from donors after brain 
death (DBD), which represents the largest source of lungs (6), or from donors after circulatory 
death (DCD). DCD source remains considerably underutilized, although there are no studies 
showing significant differences in primary graft dysfunction (PGD) risk and freedom from 
chronic lung allograft dysfunction (CLAD) between DCD and DBD (7-8). However, DCD 
markedly increases the pool of donor lungs, especially when coupled with the ex vivo lung 
perfusion (EVLP).  In some situations, the lungs may be transplanted together with a donor 
heart. While lung transplantation is a complex operation that can involve many complications, 
it can significantly improve the quality of life and the survival of patients affected by end-stage 
lung diseases.  
 
 
 
Figure 1. Schematic representation of single 
lung transplantation 
Graphical representation of single lung 
transplantation in human patients. The image is 
derived from Gregory Thompson, MD et al. 
Medical Review 2018 
The first cardiopulmonary transplantation was successfully performed by a team in Stanford 
University in 1981; in 1983 the first single LTx was performed in a patient with idiopathic 
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pulmonary fibrosis (IPF), who survived for 7 years (9). Later, in 1986, the first double LTx 
(10), and in 1990 the first double sequential transplantation was performed with the surgical 
technique that is nowadays used all over the world (11). The main difference between the 
double LTx and the double sequential LTx, which is currently used, refers to the type of airway 
anastomosis. While in the double LTx the anastomosis was performed in the trachea, provoking 
several post-surgery complications, in the double-lung sequential LTx, the anastomoses are 
made in each primary bronchus (left and right), in order to one lung ventilated while the other 
is implanted, and by that reducing the complications of the airway anastomoses (12-14).  
Approximately 30% of LTx is still single. Although the survival rate of single LTx is 
significantly lower when compared with double LTx (4.8 years in SLTx vs 7.8 years in DLTx) 
(15), it represents a good strategy to address the shortage of donor organs. This approach offers 
the possibility of transplanting two recipient patients with only one donor lung, in order to 
bypass the shortage of donor organs.   
Patients affected by end-stage lung disease are selected for LTx according to the lung allocation 
score (LAS), with a scale from 0 to 100. This score considers the survival probability of the 
recipient patient in the following year, while the patient is on the waiting list, and the predicted 
one year after LTx (16). Among the underlying diseases before LTx, chronic obstructive 
pulmonary disease (COPD) and alpha-1 anti-trypsin deficient patients (A1ATD) represent 
36.5% of the cases, idiopathic pulmonary fibrosis (IPF) 29.7%, cystic fibrosis (CF) 15.8%, 
bronchiectasis not associated to CF 2.7%, pulmonary hypertension (PH) for 4.4%, re-
transplantation for 4.1%, and some cases of sarcoidosis (17) (Figure 2). 
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Figure 2. Underlying lung diseases incidence in adult patients before LTx. 
Graphical representation of the incidence of underlying lung disease before LTx in adult patients in the period 
between 1990 and 2017. Chronic obstructive pulmonary disease (COPD), Alpha1 anti-trypsin deficiency-patients 
(A1AT), cystic fibrosis (CF), interstitial lung disease (ILD), patients that underwent a second transplantation 
(Retransplant). Source: JHLT Registry 2019 
 
While waiting for a donor lung, approximately 50% of patients die from their underlying lung 
disease because of the organ shortage (18). The donor organ shortage is mainly caused by the 
moderate number of declined donor lungs that are not considered suitable for LTx. In fact, 
donors that are selected being suitable for LTx must derive from patients with an age less than 
55 years, with excellent blood gas parameters, remote or no history of smoking, and a clear 
chest imaging (19). To overpass this problem, recently, the EVLP system has been introduced 
in Sweden and in the United States and introduced in the routine of several worldwide 
transplantation units for its ability to recondition lungs ex vivo before implantation. This system 
consists of a device capable of perfusing the graft through the vascular circulation with 
preservative solutions, reducing the formation of pulmonary edema and, by that bypassing an 
initial exclusion of the donor organ from the gas exchange criteria (20).  
Strict criteria are also followed for the recipient patients. Patients with advanced and 
progressive lung disease that, despite all medical treatments, have a reduced life expectancy, 
are indicated for LTx. Since older patients have shown a worse survival than younger patients 
(21), only patients under 65 years old are considered eligible for LTx. Moreover, physical and 
social criteria play a crucial role in the selection of proper recipients for LTx. Additionally, the 
candidates should be conscious of the pre and post-surgery procedures, should show good 
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conformity to the medical treatments, and should have adequate familiar environment. Before 
LTx, patients are aware that LTx is not a curative approach but will guarantee a longer life 
expectation. On the other hand, LTx is not indicated for patients with recent history of chronic 
infections and malignancy, because of the post-surgery immunosuppressive therapies. 
 
1.2 Clinical Diagnosis after LTx 
 
When LTx patients develop symptoms (e.g. dyspnoea, cough, fatigue, with or without fever) 
and persistent reduction (20% from the baseline FEV1 which persists for 3 weeks) in forced 
expiratory volume in 1 second (FEV1) at clinic follow-ups that may indicate allograft 
dysfunction, further examinations are required to determine the cause of lung function decline.  
One of the key lung function tests used in the clinic is spirometry.  The spirometry measures 
FEV1, which is the amount of air that can be blown out in the first second of a forced exhalation. 
Most importantly for LTx patients is the total body plethysmography that provides detailed 
information about functional parameters, in particular functional residual capacity (FRC), 
airway resistance (Raw), total lung capacity (TLC) and residual volume (RV). As the body box 
is rigid and locked, variation of air pressure that is released during the test is converted in 
volume variation that represents the lung volume (22). Over the first years after LTx, the 
spirometry is measured at regular intervals (1-3-6-12-18-24 months) to establish the new 
baseline value for the implanted lung(s), and to evaluate the presence of a pathological 
condition. A chest x-ray or a computer tomography (CT) scan, and the high-resolution 
computed tomography (HRCT) are often able to detect lung parenchymal changes and air 
trapping that are usually not detectable via a normal chest radiography (23-25). 
For further analysis, surveillance bronchoscopy associated with transbronchial lung biopsy 
(TBLB) is an useful tool to detect infections, other inflammatory responses and rejection that 
are maybe causing the organ dysfunction. BAL collection is performed by squirting sterile 100 
ml of saline solution into the airways through the fibroelastic bronchoscope and suctioning it 
back to use it for tests. These tests evaluate the inflammatory response and a potential infection. 
The airway biopsies use special forceps through the bronchoscope to get small pieces of the 
airway tissue. These are evaluated by pathologists to assess and grade any sign of rejection. 
While the clinical evaluation of acute rejection is often built on TBLB (25), airway biopsies 
are not sensitive enough to identify changes of chronic rejection, due to the technical challenges 
of reaching small and peripheral airways (26). The final decision about the diagnosis of chronic 
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lung dysfunction is based on the clinical judgment, and the results of other testing are needed 
to exclude other potential causes of the decline in FEV1.  
 
1.3 Complications of LTx 
 
Post-surgery complications are grouped into early and late ones according to the time of their 
appearance after LTx. The presence of preformed antibodies to donor organ–specific HLA 
and/or ABO blood antigens have been described as central players in hyperacute rejection, 
since they appear within 24h and quickly (27). Ischemia-reperfusion injury (IRI) represents the 
most common early complication after LTx, by occurring within 3 days after the surgery. IRI 
pathology is defined with tissue edema, thickening of the alveolar septum, of the peri-bronchial 
and perivascular wall, ground glass opacifications at CT scan (24), and pulmonary dysfunction. 
Intermediate complications that occur between 1 week and 2 months are represented by acute 
rejection, and bacterial infections, whereas viral infections start appearing in later stages. Late 
post-LTx complications are mainly represented by signs of chronic lung allograft dysfunction 
(CLAD), that occurs already at the first year post-LTx. 
 
1.4 Lung allograft dysfunctions 
 
1.4.1 Acute rejection and lymphocytic bronchiolitis (LB) 
 
In organ transplantation, the terms “acute” and “chronic” are referred to two concepts: 
reversibility and duration. Acute rejection is potential reversible and is limited in the time; 
chronic rejection is irreversible and persist for long time.  
Acute rejection (AR) is an early form of post-LTx rejection driven by T cells that recognize 
foreign major histocompatibility complex (MHC) antigens, also called human leukocyte 
antigen (HLA), and get activated. After activation, T cells migrate towards the allograft and 
prime immune responses, and by that causing tissue destruction (28). Clinical symptoms of AR 
are shortness of breath, cough with or without sputum and fever, associated to blood 
eosinophilia and neutrophilia. Pulmonary tests highlight airway dysfunctions with a decline of 
FEV1 >10%, while chest imaging shows inflammation and opacities. For a proper diagnosis of 
AR, bronchoscopy and TBB are highly recommended (26). Histologically, depending on the 
inflammatory state, AR is classified in different severity grades: A0-4, for the vascular 
evaluation, B for the airway evaluation (26). Generally, the diagnosis of grade A1-2 and B0-
BR2 is performed at high magnification, while the diagnosis of grade A2-3 and BR3 is clearly 
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defined at low magnification. Grade A0 refers to the absence of rejection; in grade A1, a 
minimal acute rejection is observed, with sparse mononuclear infiltration around small vessels, 
and the alveolar septum; in grade A2, a mild acute rejection is observed, with a frequent 
perivascular infiltration, from lymphocytes, macrophages and eosinophils that lead to sub-
endothelial infiltration and endothelial hyperplasia. The alveolar septum is slightly affected. 
Grade A3 represents the moderate form of acute rejection, since it consists of extended 
perivascular and peribronchiolar cell infiltration from lymphocytes, macrophages and some 
neutrophils. Furthermore, a diffuse alveolar infiltration and alveolar cells hyperplasia can be 
observed. Grade A4 is the most severe form of acute rejection, with a diffuse perivascular, 
peribronchiolar and alveolar mononuclear infiltration. Importantly, the endothelium and the 
alveolar septum are damaged and undergo hyperplasia. 
In 2006, in association to the previous classification based on the vascular assessment, 
pathologists decided to introduce new criteria of evaluation for the airway inflammation, also 
defined lymphocytic bronchiolitis (LB). B0 refers to the absence of bronchiolar inflammation; 
B1R defines a low grade of peribronchiolar infiltration, even though the epithelium appears 
hyperplastic. B2R refers to a high-grade airway inflammation, made of eosinophils and 
lymphocytes that extensively infiltrate the bronchial epithelium and the peribronchiolar area. 
Moreover, LB is considered to be an important risk factor for chronic rejection development 
(29). 
 
1.4.2 Chronic lung allograft dysfunction (CLAD) 
 
Chronic lung allograft dysfunction (CLAD) is one of the major limitations for long term 
survival in LTx, affecting 50% of the patients within 5 years (27). Originally, the term CLAD 
was used to refer to a homogeneous form of chronic rejection, whose diagnosis was based on 
the evaluation of FEV1 decline (31).  
In the last decade, the general knowledge in the scientific community has been based on the 
presence of two variants of CLAD, bronchiolitis obliterans syndrome (BOS), and restrictive 
allograft syndrome (RAS). The difference between the 2 phenotypes became more distinct 
when RAS was clinically defined with a decline in the total lung capacity (TLC) ≥ 10% 
compared with the baseline value, with a concomitant and persistent decline in FEV1 ≥ 20% 
from the baseline. In RAS, lungs show clear signs of pleuro-parenchymal fibroelastosis and 
interstitial pneumonia. Although RAS is less frequent than BOS, accounting for 18% of CLAD 
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patients, this phenotype causes a poorer prognosis, with a median survival of 18 months from 
LTx (32). 
Importantly, Verleden SE. et al. recently described, beside BOS and RAS, the presence of a 
third phenotype that represents 9% of the entire CLAD cohort, defined as mixed phenotype. 
The mixed phenotype is thought to be evolved from BOS and represents around 11% of BOS 
patients. This phenotype was mainly observed in patients with emphysema before LTx, that 
showed a decline in FEV1, in TLC and in the forced vital capacity (FVC)≥ 20% (33). Similar 
to RAS, imaging scans of mixed CLAD show evident signs of parenchymal fibrosis (with an 
apical, basal or diffuse distribution) (33). 
 
1.4.2.1 Bronchiolitis Obliterans Syndrome (BOS) 
 
BOS represents the most common phenotype of CLAD, covering approximately 80% of the 
cases, and heavily affects the long-term outcomes of LTx patients (34). BOS, also known for 
its popcorn-like lungs, is a disease that results in obstruction of the small terminal airways 
(bronchioles) due to a chronic inflammation (35) (Figure 3). This phenotype has been 
described to occur within the first year after LTx (JHLT Registry 2018). Clinical symptoms 
are dry cough, shortness of breath, wheezing and general weakening, and usually worsen over 
time (35).  
 
 
Figure 3. Lung imaging via high resolution computer tomography 
Representative HRCT scan of healthy lungs (on the left)(Case courtesy of Assoc Prof Craig Hacking, 
Radiopaedia.org, rID: 40797), and of lungs with bronchiolitis obliterans syndrome phenotype, showing a so-
called pop-corn phenotype, bronchiectasis, air trapping and bronchial thickening (on the right) (image derived 
from Xie BQ, et al. PLoS One 2014) 
 
BOS pathogenesis has been shown to quickly develop, in parallel with a progressive decline of 
the pulmonary function. Clinically, it is defined as a persistent decline in FEV1≥ 20% from the 
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baseline, without any chance in TLC. According to the decline rate of FEV1 (31), several stages 
of the disease have been described (Table 1). BOS stages are classified according to the % 
decline in FEV1 values, in BOS-0 when the FEV1 value is >90%; in BOS-1 when the FEV1 
value is between 66 and 80%; in BOS-2 when the FEV1 value is between 51 and 65%, and in 
BOS-3 when the FEV1 value is ≤50% (23, 28). 
The histological hallmark of BOS consists of fibrotic luminal obliteration and advanced 
mononuclear cell infiltration of the respiratory and terminal bronchioles (36) (Figure 6). HRCT 
scans of transplanted lungs have shown in BOS signs of bronchiectasis, air trapping and peri-
bronchial thickening (37). Differently from the acute rejection, the heterogeneous nature of 
BOS makes it difficult to be diagnosed via transbronchial lung biopsies (TBB). After LTx, 
patients are treated with moderate dosages of immunosuppressants in order to prevent forms 
of rejection. Several combinations of immunosuppressive agents like tacrolimus, cyclosporine, 
mycophenolate, and corticosteroids (e.g. prednisone) are used to treat BOS patients. However, 
intensive treatment with corticosteroids (≥30 mg/day of prednisone) has shown any beneficial 
effect in attenuating lung function decline; in addition, numerous serious and long-lasting side 
effects have been associated with this therapy, such as osteoporotic fractures, cataracts and 
indigestion (38). Tacrolimus, also known as FK506, is a strong immunosuppressive drug that 
prevents the white blood cells from attacking the graft. Tacrolimus has been shown to be crucial 
for a longer survival after transplantation. Patients, that were previously treated with 
cyclosporine, switching to tacrolimus have shown to successfully reduce the lung function 
decline, and to inhibit BOS progression. Most importantly, replacing cyclosporine with 
tacrolimus also reduces the incidence of nephrotoxicity and hyperglycaemia, usually reported 
after long-term cyclosporine treatment (39-40). Another well-established drug for BOS 
treatment is Azithromycin, a potent antibiotic, which was demonstrated to efficiently prevent 
disease-progression. Approximately 40% of LTx patients treated with Azithromycin, showed 
a complete reversal of FEV1 decline when BAL neutrophilia was detected (41). Interestingly, 
previous studies have highlighted the anti-inflammatory effects of Azithromycin in several 
organs, via its ability to drive macrophage polarization towards an anti-inflammatory 
phenotype (M2 macrophages) (42), and to increase the phagocytic activity of alveolar 
macrophages towards apoptotic bronchial-epithelial cells, limiting secondary injury damages 
(43). In cases where bronchiolitis obliterans syndrome is progressive and severe, extracorporeal 
photopheresis has also been successfully used to slow the decline in lung function from 
bronchiolitis obliterans syndrome (44). 
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Table 1. BOS severities according to the decline of FEV1 
FEV1 % BOS severity 
81-90 0 
66-80 1 
51-65 2 
≤50 3 
 
1.4.2.2 Restrictive Allograft Syndrome (RAS) 
 
In 2011, Sato et al. described for the first time a new form of CLAD, called restrictive allograft 
syndrome (RAS). RAS is characterized by a diffuse alveolar damage and excessive fibrosis, 
that affects the alveolar septum, the pleura, and can shows, similar to BOS, bronchial 
obliterations (Figure 4 A).  Importantly, the predominant fibroproliferation in the alveolar 
septum (Figure 4B), observed only in RAS, makes the lung stiff and causes an important 
decline in the total lung capacity. Clinically, RAS is diagnosed with a persistent decline in 
FEV1 >20% and TLC >20%. Due to the severe phenotype, the survival of RAS patients is less 
than 18 months when compared with 46 months of BOS patients (30).  
 
 
 
Figure 4. Histological 
comparison between 
BOS and RAS tissue 
(A) Hematoxylin and 
eosin staining of lung 
tissue from explanted lung 
tissue (BOS in the right 
panel, RAS in the left 
panel) (original 
magnification ×100). (B) 
Immunofluorescence 
staining for α-smooth 
muscle actin (α-SMA), 
marker of myofibroblasts 
(red), and nuclei (blue) 
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1.5 Lung allograft biomarkers 
 
When the spirometry values of LTx patients drop, and physical symptoms are observed, further 
tests are required in order to exclude the presence of infections and/or rejection. Several centers 
adopt routine tests, to evaluate the total lung capacity (TLC) and diffusion lung capacity; blood 
tests, including biochemistry and coagulation; bronchoscopy with/without transbronchial 
biopsy; microbiological tests. 
Growing evidence shows the involvement of the immune system in BOS development. BAL 
neutrophilia is used as marker to distinguish BOS patients from stable LTx patients. A trend 
towards high levels of neutrophils in BAL of stable LTx patients is used to predict the 
development of BOS by 3-9 months (45). RAS shows a restrictive physiology, and diffuse 
inflammation and fibrosis that affect alveolar septum, pleura and interlobular interstitium. RAS 
can be distinguished from BOS, for the presence of diffuse signs of alveolar damage, called 
diffuse alveolar damage (DAD). On the other hand, BOS shows an obstructive physiology, 
associated with air-trapping, and peri-bronchial inflammation (30).  
Vanaudenaerde BM et al. sub-classified BOS patients into NRAD and fBOS. NRAD refers to 
the BOS patients with BAL neutrophilia that respond to Azithromycin therapy with a beneficial 
long-term effect and long survival (45). BAL neutrophilia was shown to be associated with LB 
which has been described as risk factor of BOS (28). fBOS patients do not respond to 
azithromycin, and have less BAL neutrophilia and tissue inflammation, but marked signs of 
airway fibrosis that cause air-trapping (45). However, BOS and RAS cannot be distinguished 
based on BAL, since both show high number of neutrophils in the BAL (46). Therefore, several 
soluble mediators have been described to be specific only for BOS. Elevated amount of CXCR3 
ligands that bind CXCR3 receptor on the surface of several immune cells, may predict BOS 
development (47). Of recent discovery, donor derived circulating cell free DNA (ddcfDNA), 
that are released from dead cells, have been showed increased in the BAL of BOS patients (48). 
A BAL gene expression profile from LTx patients reported higher expression of genes 
encoding for T-cell receptor, for the costimulatory molecules CTLA4 and CD28, and for T-
cell effectors molecules, in patients with acute rejection when compared with patients without 
signs of rejection (49). Active cytomegalovirus (CMV) infection is considered an important 
cofactor for BOS development in patients that are do not have an appropriate immune system 
(50). One hallmark of BOS lung tissue is the influx of immune cells into the peribronchiolar 
area of allograft lungs. Among these, T and B cells have been described to infiltrate the 
submucosa of bronchial and vascular epithelium and contribute the formation of de novo 
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lymphoid tissue. The presence of lymphoid tissue may lead to immune responses in terminal 
airways where irreversible signs of rejection are observed (51-52). However, macrophages 
infiltration could promote BOS progression already at early stage of the disease.  
 
1.6 Lung macrophages 
 
Under homeostatic conditions, lung airways are populated by macrophages, that normally 
account for 95% of the airspace space, about 1-4% of lymphocytes, 1% neutrophils and less 
than 1% of dendritic cells (53). 
Macrophages originate from the bone marrow and migrate through the blood circulation 
towards different tissues where they differentiate into a variety of phenotypes in response to a 
wide spectrum of signals from the environment (54). There is a substantial heterogeneity 
among each macrophage population that reflects their different roles within the tissue. This 
heterogeneity is found in their morphology, function, as well as on the type of cytokines they 
secrete (55).  
On the basis of the stimulation and mediators released, macrophages are usually grouped into 
two distinct phenotypes: the classically activated (M1), also called pro-inflammatory 
macrophages, that are responsive to type 1-derived cytokines (IFN- and LPS), and the 
alternatively activated (M2) macrophages respond to type 2-derived mediators IL-4 and release 
anti-inflammatory cytokines to support tissue regeneration (Figure 5). 
In the lung, there are 2 distinct populations of macrophages that have the ability to self-renew 
locally independently of their circulating progenitors: alveolar macrophages (AMs) and 
interstitial macrophages (IMs), each one with specific properties and functions (56-57). 
Macrophages are highly plastic and are able to change their phenotype and function during 
pulmonary diseases. Phagocytosis and secretion of antimicrobials and pro-inflammatory 
mediators is the main task of alveolar macrophages, that play a central role in in maintaining 
immunological homoeostasis and host defence in the lung (58). When these activities are not 
successful in defending the host, macrophages may act as antigen presenting cells (APCs), 
presenting antigens to T and B cells, and activate their response (59). In addition to 
physiological conditions, the role of macrophages in various organ transplants is still 
controversial. 
Several studies have reported deleterious effects originating from macrophages that were 
shown to attack the allografts and cause organ rejection in both acute and chronic conditions. 
In chronic rejection after kidney transplantation, macrophages are currently used as biomarkers 
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since their amount is strongly associated with disease worsening (60-65). On the other hand, 
other studies have highlighted the presence of a certain subtype of macrophages, regulatory 
macrophages (Mregs), that might protect the organ after implantation (66), suggesting that the 
functional role of macrophages is defined by their phenotype. In the context of organ rejection, 
after an initial phase of CD4+ T cells-mediated priming, macrophages showed the ability to kill 
graft cells independently from other lymphoid cells (67) and triggered allo-immunity (68). 
Accordingly, deletion or inhibition of macrophages reduced organ damage and extend 
transplant survival (69). Similar to pre-clinical studies, clinical studies have reported a strong 
association between macrophages infiltration and graft rejection (70-72). Moreover, a high 
incidence of pulmonary fibrosis (73) was found when pro-inflammatory macrophages infiltrate 
the graft (74-76). Consistent with these findings, the inhibition of pro-inflammatory mediators 
demonstrated the attenuation of the fibrotic phenotype (77). 
Although macrophages were described to be involved in several type of diseases and in 
different organ transplantation models, their role in the pathogenesis of BOS has not yet been 
investigated. 
 
Figure 5. Macrophage polarization 
Tissue macrophages differentiate into a pro-inflammatory M1 phenotype under the stimulation of IFN-gamma, 
LPS and TNF-α. Consequently, they release other cytokines that promote the pro-inflammatory response; under 
IL4 and IL13 stimulation, macrophages differentiate into an anti-inflammatory M2 phenotype, usually described 
in the tissue repair process 
 
1.7 Other molecular lung allograft features 
 
In order to identify predictive signs of BOS development, clinicians rely on clinical symptoms 
but also on the patchy ground glass opacity on HRCT scans as well as the state of fibrosis 
(Figure 5). The tissue fibrosis is often associated with the destruction of the airway wall, and 
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a severe pulmonary dysfunction (77). In particular, collagen and elastic tissue staining facilitate 
the identification of injured and/or obliterated airways (30). 
 
 
Figure 6. Histological features of BOS 
Representative image of hematoxylin eosin (A) and Masson Trichrome (B) staining of BOS lung tissue, that 
show mononuclear infiltration and accumulation of collagen (78) 
 
The pathogenesis of the fibrosis has been investigated in numerous studies, which defined it as 
a pathological feature of chronic inflammatory diseases. Don C. Rockey and his colleagues for 
instance suggested the presence of 4 main phases that all contribute to the tissue scarring. The 
first phase refers to the initiation of the response, driven by the injury of the tissue which 
triggers the activation of effector cells in the second phase, and lead to the synthesis and 
deposition of the extracellular matrix (ECM) components in the third phase, prompting the 
progression of fibrosis and organ dysfunction in the fourth phase (79).  In general, when the 
injury occurs, resident epithelial cells and/or endothelial cells start releasing inflammatory 
mediators, such as cytokines, chemokines, and growth factors, that lead to the recruitment of a 
wide range of innate immune cells, mainly macrophages, neutrophils and lymphocytes (80). 
These inflammatory cells release other soluble mediators (e.g. transforming growth factor 1,  
also called TGF-β1, interleukin 4, also called IL-4, interleukin 13, also called IL-13) and by 
that activate fibroblasts and myofibroblasts, which have been identified as key effector cells in 
many organs, responsible for the synthesis of ECM proteins (80-81). Among the ECM proteins 
that are usually found in fibrotic areas, interstitial collagens (types I and III) and fibronectin 1 
are the most frequent. In addition, activated fibroblasts express smooth-muscle proteins (SMA) 
that enable that to contract (81-82), causing the alteration of the tissue structure and promoting 
organ failure.  
On the molecular level, of all pro-fibrotic mediators reported (80), TGF-β1 is the most 
intensively studied and central player in fibrotic diseases (83-85). TGF-β1 is released in the 
extracellular space bound to a latency-associated protein (LAP) that prevents its rapid 
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activation. Separation and activation can be achieved through different triggers that are released 
by inflammatory cells in the extracellular space, like plasmin, calpain-1, thrombospondin, 
integrins and matrix metalloproteinases (86). Once released, active TGF-β1 binds to a serine–
threonine kinase type-II-receptor (TGF-β1RII) that recruits and phosphorylates a type-I-
receptor (TGF-β1RI). TGF-β1RI subsequently phosphorylates SMAD2/3 proteins that bind 
SMAD4, and by that they mediate SMAD4 translocation into the nucleus. Downstream 
signalling results in the up-regulation of pro-fibrotic genes expression, including ECM proteins 
(Figure 6). TGF-β1 is synthesized and secreted by inflammatory cells (e.g. macrophages) and 
by effector cells (e.g. fibroblasts), thereby functioning in both in autocrine and paracrine way.     
 
 
 
Figure 7. Schematic description of TGF-
β1 signaling 
The binding of TGF-β1 ligand to the 
extracellular receptor triggers the signal 
cascade intracellularly, through the 
posphorilation of smad2/3 proteins, that build 
up a complex with smad4 protein and 
translocate into the nucleus, where the 
transcription of genes associated to the 
fibrogenesis is promoted (87) 
 
1.8 Cystatin C and Cathepsin B 
 
TGF-β1 was shown to be regulated by at least five well-known endogenous molecules (86). 
Indeed, among them, Cystatin-C (CysC) was shown to prevent epithelial-mesenchymal 
transition (EMT) in cancer cells (88), through the inhibition of TGF-β1-signaling in fibroblasts. 
CysC was reported to be significantly reduced in murine and human lungs when affected by 
interstitial fibrosis, while its restoration attenuated lung fibrosis (89). CysC belongs to the 
cystatin superfamily and is known to be the most relevant biological inhibitor of cysteine-
proteases (cathepsins) of the papain family, such as Cathepsin B (CatB), Cathepsin L (CatL), 
Cathepsin S (CatS) and Cathepsin H (CatH) (90). Biologically, CysC is found in all cells, and 
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tissues, and is continuously secreted. Because of its size of 16 kilo Dalton and basic pH (~9.0), 
its half-life is particularly short, since it is rapidly cleared into lysosomes (91).  CysC consists 
of one single domain and one signal peptide and exerts a protective role from the cathepsins 
that are released or leaked from lysosomes (92).  To exert its inhibitory function, CysC binds 
to the active site of the cathepsins via a N-terminal tripeptide sequence L9-V10-G11 that 
interacts with the pockets S3 S2 S1 of the target cathepsins. Of relevance is L9 (Leucin) which 
is crucial for the binding and contribute to the formation of a V-shaped structure to occlude the 
active site of these protease (93).   
One of the most studied targets of CysC is Cathepsin B (CatB), which is widely studied in 
association with chronic lung diseases and in the context of tissue fibrosis (94-95). CatB is 
required for the elimination of damaged organelles, for the degradation of denatured proteins 
by autophagy, and for the recovery of damaged cells after tissue-injury. CatB is a lysosomal 
cathepsin and exists in diverse organisms including bacteria, viruses, plants, and animals. Its 
expression is highly regulated, and the protein is synthesized in a pro-form (proCatB), in which 
the signal peptide is needed for further post-translational modifications. In fact, a truncated 
form, lacking the signal peptide and part of the pro-peptide, was reported to be found in a not 
functional state in the cytoplasm since it is unable to reach the Golgi apparatus neither the 
lysosomes (96). The secretion of proCatB occurs as a result of increased expression, however 
the secretion of active CatB (aCatB) depends on the activity of other pro-inflammatory 
proteases (e.g. Cathepsin G, and neutrophil elastase), on acidic pH conditions and autocatalysis 
(97). CatB plays an important role in processing proteins in lysosomes and in the extracellular 
space, by hydrolysing the precursor peptide, from a zymogen form into an active form. 
Importantly, it consists of an active site, composed of cysteine (Cys) 25, histidine (His) 159, 
and asparagine (Asn) 175 (98). Differently from other cathepsins, CatB is unique because it 
exhibits two types of enzymatic activities: it acts as exopeptidase (carboxydipeptidases) or 
endopeptidase, due to the presence of a sequence of ∼20 amino acid (105-125), called 
“occluding loop” (98). The exopeptidase activity occurs at pH 5 (99) which is found in 
lysosomes (100). By using a fluorescence resonance energy transfer (FRET) system, a previous 
study was able to define arginine as preferred substrate of CatB at position P1 when it acts as 
exopeptidase (101). In addition, the aminoacids leucine, serine and alanine can also be 
recognised and bound.  Importantly, CatB is active at acidic as well as neutral pH (102). 
One fibrosis-associated factor and target of CatB is TGF-β1. CatB was shown to implement 
TGF-β1 signaling (103) and to be significantly increased in several fibrotic diseases, such as 
bleomycin-induced lung fibrosis (94) and advanced liver fibrosis (84). Interestingly, lung tissue 
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from BOS patients revealed remarkably increased levels of TGF-β1 (104). However, the role 
of CatB in this disease have not been yet investigated. 
 
1.9 Experimental murine models of LTx 
 
Due to poor knowledge of BOS development and poor drug response, animal models of BOS 
could clarify the pathogenesis of the disease. For this purpose, mice and rats have been used as 
a chronic rejection model for the past 30 years. 
 
1.9.1 Tracheal transplantation model 
The first animal model used for the study of BOS development was the murine heterotopic 
tracheal transplant model (HTT). The HTT, based on the genetic mismatch between donor and 
recipient mice, was able to reproduce airway obliteration. After Tx, between day 0 and 7 an 
important subepithelial and peri-tracheal mononuclear infiltration started, followed at day 21 
by tracheal obliteration which was comparable to human OB (105). Despite a high level of 
similarities between HTT model and human OB pathology, and the surgical advantages, 
several limitations were considered. First, the trachea does not act as a functional airway; 
second, the trachea does not have a primary vascularization, which is thought to play a crucial 
role in the rejection; third, BOS is a disease that affects small and peripheral airway, not large 
airways (106).  
 
1.9.2 Orthotopic left lung transplantation mouse model 
To better investigate the pathomechanism of CLAD, we used a mouse model of left LTx with 
a single mismatch. Donor lungs from mice having a HLA-A2–knock-in (HLA) on a C57BL/6 
(B6) background were implanted in B6 recipients. B6 donor lungs implanted in B6 recipients 
(B6→B6 mice) were used as experimental controls. The single mismatch was able to reproduce 
the phenotype of LB after a period of 2 months (52). Our mouse model (HLA→B6) clearly 
shows pathological changes that occurs in human BOS, including ECM deposition in peri-
vascular and peri-bronchiolar areas, peri-bronchial mononuclear infiltration, loss of clara cells, 
the formation of immune follicles around vessels and airways, bronchiolar epithelial cell 
dysplasia, and bronchiolar epithelial thickening (25). Plasma donor specific antibodies (DSAs) 
have been considered risk factor for BOS development (4) in LTx patients. In agreement with 
human findings, our mouse model of LB (HLA→B6) exhibited high titers of DSA (26) at 2 
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months post-LTx. Considering that LB is a precursor of OB in BOS (28), our mouse model of 
LTx is an useful tool to investigate the initiation of BOS progression. However, the main 
limitation of this model is the lack of airway obliteration, in particular in small and peripheral 
airways, as described in human.  
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2. AIM OF THE PROJECT 
 
Bronchiolitis obliterans syndrome (BOS) is a major complication after LTx, affecting the long-
term outcomes and life expectancy of patients. Approximately 50% of transplanted lungs 
develop BOS within 5 years from the surgery. Histopathological evaluations have highlighted 
in the late stage of the disease that distal small airways, vessels and alveolar spaces are 
dramatically marked by signs of inflammation and fibrosis (30) (78), that all lead to a persistent 
drop of FEV1 % ≥20, and organ failure. However, the main triggers that promote BOS 
development in human patients have not been identified yet. One of the major reasons for this 
scientific gap is the limitation of human samples for research. Translational studies are 
restricted to bronchoalveolar lavage fluid (BALF) and peripheral blood. Lung tissue sampling 
is mainly available from patients that have already reached a very late stage of the disease, 
rendering it hard to investigate early-events that may trigger disease progression. Moreover, if 
airway biopsies are available, these are not always a reliable specimen capable of reproducing 
the disease due to technical limitations. 
Therefore, the objective of this study was to investigate potential markers that contribute to the 
development of BOS, using BALF samples collected from LTx patients at different stages of 
the disease. This, coupled with our LTx mouse experimental model of LB, enabled us to 
identify potential drivers of the disease. 
Previous studies have shown Cystatin-C (CysC), the most relevant endogenous regulator of 
Cathepsins´ activity, to prevent epithelial-mesenchymal transition (EMT) and fibrogenesis in 
cancer cells as well as in fibroblasts through the inhibition of TGF-β1-signaling in fibroblasts. 
Consistent with this, Cathepsin B (CatB), one of the targets of CysC, was already reported to 
be notably increased in the context of lung fibrosis as well as in liver fibrosis.  
We hypothesized that the inflammation, driven by enhanced CatB activity, leads to a 
progressive accumulation of collagen over the pathogenesis of BOS.  
To elucidate the function of Cathepsin-B in BOS pathogenesis, we first determined the 
expression of CysC in lung tissue from transplanted patients, and then evaluated the activity 
and protein expression of CatB as well as the levels of newly formed collagen in BALF samples 
from LTx patients, at different time points of the disease. To investigate the impact of CatB in 
the pathophysiology of BOS, we used an in vivo orthotopic left-lung transplantation mouse 
model.  Mechanistically, CatB-mediated BOS progression was addressed by using an in vitro 
cell culture model of BOS pathogenesis. 
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To elucidate the function of Cathepsin-B in BOS pathogenesis, we first determined the 
expression of CysC in lung tissue from transplanted patients, and then evaluated the activity 
and protein expression of CatB as well as the levels of newly formed collagen in BALF samples 
from LTx patients, at different time points of the disease. To investigate the impact of CatB in 
the pathophysiology of BOS, we used an in vivo orthotopic left-lung transplantation mouse 
model. Possible mechanisms of CatB-mediated BOS progression were addressed by using an  
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3. MATERIALS AND METHODS 
 
3.1 List of materials 
 
Reagents 
 
Table 2. Solutions, reagents and cell culture media used in the study 
 
Name Source 
0.25 % Trypsin-EDTA Sigma Life Science 
Acrylamide:N,N´- Methylene – Bisacrylamide 40% (29:1) Carl Roth 
Ammoniumsulfate (APS) ZYTOMED Systems 
Amersham ECL Prime Western blotting detection reagent Sigma 
β – Mercaptoethanol Sigma Life Science 
Blot Stripping Buffer Thermo Scientific 
Bovine serum albumin (BSA) Life Technologies 
Complete (Protease Inhibitor) Life Technologies 
Dulbecco's Modified Eagle Medium (DMEM) Gibco, Thermo Fisher 
Scientific 
DNase/RNase free water Promega 
Distilled water ZYTOMED Systems 
dNTP Mix 10mM 1000µl Carl Roth 
EDTA Buffer pH 9 Roche Diagnostics 
Ethanol Sigma 
Fetal Bovine Serum (FBS) Bio and Sell 
Fluorescent Mounting Medium Dako 
Isopropanol Carl Roth 
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Name Source 
4x Laemmli Sample Buffer Bio-Rad 
LPS Sigma 
IFNgamma Biolegend 
IL4 Biolegend 
CA074 Sigma-Aldrich C5732 
SB431542 Tocris 
Methanol Sigma-Aldrich 
MuLV Reverse Transcriptase 5000U (Reverse 
Transcriptase) 
Carl Roth 
MgCl2 (25mM) Life Technologies GmbH 
Milk Powder Carl Roth 
Pen for histology Dako 
Protein Standards Bio-Rad 
Phosphatase Inhibitor (Vanadate) Life Technologies 
Penicillin/Streptomycin Gibco, Thermo Fisher 
Scientific 
PBS Applied Biosystems 
PCR Buffer II + MgCl2 New England Biolabs 
Random Hexamers 50µM Thermo Fisher Scientific 
RNase Inhibitor 20 U/µl, 2000U Bela-pharm 
PowerUp Syber green Mastermix Thermofisher 
SDS AppliChem 
Temed Bio-Rad 
Tween-20 Sigma-Aldrich 
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Name Source 
Xylol Sigma – Aldrich 
H2O2 30% H1009 Sigma Aldrich 
Avidin/Biotin SP-2001 Vector Laboratories 
Peroxidase substrate SK-4105 Vector Laborratories 
Biebrich Scarlet-Acid Fuchsin Solution HT15-1 Sigma Aldrich 
Phosphomolybdic Acid Solution HT15-3 Sigma Aldrich 
Aniline Blue Solution (Collagen staining) HT15-4 Sigma Aldrich 
 
Buffers and Stock solutions 
Table 3. Composition of buffers and stock solutions 
 
Buffer Name Ingredients 
10x PBS 
 
Na2HPO4 
KH2PO4 
Nacl 
KCl 
PBS-T / Washing Buffer 1x PBS 1% Tween-20 
Running 1,5M Tris – HCl pH=8.8 
RIPA 
 
NaCl 150 mM 
Tris pH7,2 10 mM 
SDS 0,1% 
Triton x100 1% 
Deoxycholate 1% 
EDTA 5mM 
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Buffer Name Ingredients 
Transfer 
150mM Glycine 
20mM Tris 
20% Methanol 
Fuchsin Solution 
0.9% Biebrich Scarlet 
0.1%Acid 
1% Fuchsin 
Phosphomolybdic acid 10% Phosphomolybdic acid 
Collagen staining blue solution 
2.4% Aniline blue 
2% Acetic acid 
 
Primers for qPCR 
 
Table 4. qPCR primers used in this study 
 
Target gene Forward Reverse 
Mouse hprt3 TCC TCC TCA GAC CGC TTT T CCTGGTTCATCATCGCTAATC 
Mouse hprt2 CCT AAG ATG AGC GCA AGT TGA A 
CCA CAG GAC TAG AAC ACC TGC 
TAA 
Mouse ctsb AGCCATTTCTGACCGAACCT TGGTAAGCAGCCTACATGAGAA 
Mouse tgfβ-
1 
TGA CGT CAC TGG AGT TGT AGT 
TGT ACG 
GGT TCA TGT CAT GGA TGG TGC 
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Antibodies 
Primary antibodies 
 
Table 5. Primary antibodies used in this study 
Primary Antibody Name Source 
Anti-Galectin 3 (mouse) 
Santa Cruz 
Biotechnology 
Anti-Galectin 3 (rabbit) 
Santa Cruz 
Biotechnology 
Anti-β-actin Abcam 
Anti-Cystatin C (rabbit) Abcam 
Anti-Cathepsin B (mouse) Abcam 
Anti-Collagen 1 (rabbit) Rockland 
Anti-Fibronectin 1 (rabbit) Abcam 
Anti-Ly6G (rat) Biolegend 127602 
Anti-CD3 Abcam clone SP7 
Anti-CD45R Labome clone RA3-SB2 
Anti-HLA.A2 Abcam 
Anti-NOS2 
Santa Cruz 
Biotechnology 
Anti-pSmad3 Cell signaling 
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Secondary antibodies 
 
Table 6. Secondary antibodies used in this study 
 
Secondary antibody name Source 
DAPI Life Technologies 
Anti-rat Abcam 
Anti-rabbit Merk Millipore 
Anti-mouse Life Technologies 
Alexa Fluor 568 anti-goat  Life Technologies 
Alexa Fluor 488 (anti-rabbit ) Life Technologies 
Alexa Fluor 488 (anti-mouse)  Life Technologies 
Alexa Fluor 555 (anti-rabbit)  Life Technologies 
 
Commercial Kits 
 
Table 7. List of commercial kits used in the study 
 
Kits Company 
peqGOLD Total RNA Kit PEQLAB Biotechnology 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 
Human Pro-collagen 1a1 ELISA Kit R&D System 
Cystatin C ELISA ELISA Kit R&D System 
Active TGF-β1 ELISA Kit Boster Picokine 
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Laboratory equipment 
 
Table 8. List of devices used in the study 
 
Devices Company 
Centrifuge 5430 Eppendorf AG 
Centrifuge Galaxy 16 DH VWR International 
Cool centrifuge, Mikro 220R Andreas Hettich 
Cool centrifuge, Rotina 35R Andreas Hettich 
Heat block HBT 130 
DITABIS, Digital Biomedical Imaging Systems 
AG 
Heat block Thermomixer Compact Eppendorf AG 
Haemocytometer Neubauer Karl Knecht Assistent 
Incubator MCO-18AC SANYO Component Europe 
Magnetic Steerer IKAMAG REO IKA Werke 
Microtome Hyrax m55 Carl Zeiss Microscopy 
Microscope Carl Zeiss Microscopy 
Multiplate Reader Infinite 200 Pro Tecan Trading AG 
NanoDrop® ND-1000 spectrophotometer Thermo Scientific 
PCR Thermo cycler (Nexus Eco, Nexus 
Gradient) 
Eppendorf AG 
Pipettes Eppendorf AG 
Pipetboy INTEGRA Biosciences 
qRT – PCR Thermocycler StepOne™ Applied Biosystems 
Scanner Mirax Desk Carl Zeiss Microscopy 
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Shaking incubator IKA Werke 
SDS PAGE Chamber Bio-Rad Bio – Rad Laboratories 
Scale, Precisa XT 6200C-FR Pesa Waagen AG 
Voltage device Bio-Rad Bio – Rad Laboratories 
Vortexer, VM3 Ingenieurbüro CAT M. Zipperer 
Vortexer, Vortex Genie 2 Scientific Industries 
Western Blot Chamber, Bio-Rad Bio – Rad Laboratories 
96 wells qPCR plate Thermo Scientific 
FlexiVent ScireQ 
Myrax scanner Zeiss 
Microdismembrator Sartorius 
 
Fluorescence resonance energy transfer (FRET) materials 
 
Table 9. FRET substrate used in this study 
 
Sequence Target Company 
Z-Arg-Arg-AMC Cathepsin B Bachem, 404789 
 
Table 10. Recombinant proteins used in this study 
 
Protein Company 
Cathepsin B R&D System 
Transforming growth factor 1 (TGF-β1) R&D System 40B-002/CF 
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3.2 Molecular biological methods 
 
RNA isolation 
RNA isolation from adherent cells was performed via PeqGOLD kit. For 12 and 24 well plates, 
cell lysates were obtained by adding 400 µl of lysis buffer into each well. Cell lysate was 
applied to a DNA Removing Column and centrifuged for 1 min at 12.000xg. DNA Removing 
Columns were discarded, and the eluted solution of each sample was transferred into new 1.5 
ml tubes. 400 µl of 70% Ethanol was added into each tube and the sample was mixed via 
vortex, then loaded on RNA binding columns followed by a centrifugation step at 10,000xg 
for 1 minute. The eluted solution was thrown away and RNA binding columns were placed in 
2 ml collection tubes. The columns were washed by adding 500 µl of RNA Wash buffer 1 and 
centrifuged at 10,000xg for 15 seconds. The eluted solution was discarded and 600 µl of RNA 
wash buffer II was added to the columns. A centrifugation step at 10,000g for 15 seconds 
followed by a second centrifugation for 2 min was important in order to remove all the ethanol. 
For an efficient elution, RNAase free water was heated to 70°C, and 40 µl was added into each 
column and incubated for 5 min. The columns were centrifuged at 5000xg for 1 min and the 
eluted samples were collected. RNA concentration and purity were determined via Nano Drop. 
Sample were stored at -80°C for further use. All centrifugation steps were performed at room 
temperature (RT). Nucleic Acid- RNA-40 setting was used for measurements, considering for 
pure RNA sample a ratio of A260/A280 nm around 2. 
 
Synthesis of cDNA via RNA-reverse transcription (RT) 
The concentration of RNA was adjusted to 25-50ng/μl with RNase free water. Samples were 
incubated in a thermo-shaker (Heat block Thermomixer Compact, Eppendorf) at 70° C for 10 
minutes followed by incubation on ice for 5 minutes. Master mix solution was prepared for a 
20 μl of final volume per sample: 4 μl of 10x Buffer II, 8 μl MgCl2 (25mM), 2 μl of dNTPs 
(10mM), 2 μl of Random Hexamers, 1 μl of RNase-Inhibitor, 2 μl of Reverse Transcriptase 
and 1 μl of dH2O. The master mix (20 µl mix per sample) was added to 20 µl of RNA samples. 
Reverse transcription procedure was performed on the Thermocycler (PCR Thermo cycler, 
Nexus Eco, Nexus Gradient) according to the following protocol: for 10 min at 20° C, 75 min 
at 43° C and 5 min at 99° C. Finally, 60 μl RNase free water was added to each tube to dilute 
the samples. Samples can be stored for further analysis. 
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Real time quantitative polymerase chain reaction (Real time qPCR) 
In order to determine the expression level of genes of interest, real time quantitative-PCR was 
performed using SYBR® GREEN PowerUP. SYBR® GREEN is a dsDNA-binding dye that 
intercalates into dsDNA in a non-specific manner. Specific primer that were pre-tested bind to 
parts of the gene of interest and ensure the proper amplification. The newly produced double 
stranded DNA molecules produce a fluorescent signal with SYBR® GREEN that can be 
detected and quantified by the qPCR machine (PCR Thermocycler StepOne™, Applied 
BioSystem). For reliable results, a housekeeping gene (in this study Hprt was chosen) as a 
reference is used in each qPCR. qPCR reactions were prepared as followed: 10 µl of syber 
green buffer, 12 µl of distilled water and 1 µl of forward and reverse primer (from 1:10 stock 
solutions), 2 µl of cDNA was added into this master mix in 96-well qPCR plates from Applied 
Biosystems. The reaction was performed using a Thermocycler StepOne™ according to the 
following protocol: 5 min at 95°C, 5 sec at 95°C, followed by 5 sec at 59°C, 30 sec at 72°C 
for 45 cycles and 15 sec at 95°C. The gene amplification program provided melting curves 
that ensured the presence of proper DNA molecules. The relative expression of each gene was 
normalized to the average of the Ct value of HPRT expression using the formula 2-ΔCt, where 
ΔCt = Ct target – Ct control. The results were analysed in GraphPad prism 8 software and 
depicted as graphs. 
 
3.3 Protein analysis 
 
Protein isolation  
In order to isolate protein from cells, medium was discarded and cells that were previously 
seed in either 6 or 12 well plates were washed with sterile cold PBS. Plates were put on ice 
and all further steps were performed on ice to avoid degradation of the proteins. 60-100 µl of 
cold RIPA buffer supplemented with protease inhibitors, were added into each well. Adherent 
cells were scratched from the plate and collected in precooled tubes. In order to enhance the 
protein yield, samples were snap-frozen in liquid nitrogen for 5 seconds. A thowing step 
followed and samples were vortexed. Samples were centrifuged at 16000 g for 15 minutes at 
4°C, and supernatants were collected into new precooled tubes.  
In order to isolate protein from tissue, frozen tissue needs to be powdered. 2-3 grams of the 
powder was dissolved in RIPA buffer supplemented with inhibitors. Incubation on ice and 
vortex-steps followed for 20 min. Centrifugation is performed similar to the upper paragraph. 
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Protein concentration detection via BCA 
The Thermo Scientific™ Pierce™ BCA Protein Assay is a detergent-compatible formulation 
for measurement of protein concentration, that is based on chelation of bicinchoninic acid 
(BCA). BCA reacts with complexes between copper ions that are reduced by peptide bonds in 
proteins, and the end product gives purple colour depending on the concentration of protein in 
the reaction which absorbs light at 562 nm (Walker, 1994). Standard curve was made using 
serial dilutions of bovine albumin protein in RIPA buffer (from 2 mg/ml to 0.025 mg/ml). 
Samples were added at defined dilution factors into each well of a 96 well plate using RIPA 
buffer as diluent. The working buffer was prepared according to the standard-protocol by 
mixing 50 parts of BCA Reagent A with 1 part of BCA Reagent B, and 200 µl were added to 
each well. After 30 min of incubation at 37 °C, the absorbance was measured on a Tecan plate 
reader at 562nm. 
 
Western blotting 
In order to separate proteins according their molecular weight (MW) on SDS-PAGE, a gel was 
prepared consisting of two layers: stacking (5%) and separating (10 and 12% of Acrylamide). 
10-20µg of protein samples supplemented with 4x Laemmli loading buffer were incubated at 
95°C for 10 minutes, then centrifuged to remove bubbles and kept on ice for 5 min. Samples 
were loaded on gels, and run at 100 V for 10 min, then at 120 V for 60 min. 
PVDF membranes were used for immunoblotting and placed into the transfer chamber filled 
with fresh 1x transfer buffer and was run at 100 V for 60-90 min. Blocking of the membranes 
was performed at room temperature for 2 hour using 5 % milk in 1x PBS-T buffer (Phosphate 
buffered saline + 0.1% Tween 20). Blocking was followed by primary antibody incubation at 
4° C overnight. Primary antibodies were diluted in 1% milk or 1% Roti according to the 
recommended dilution for each antibody, as follows: primary antibody against CatB (1:400 
ab58802), and (1:500 MAB965 R&D System); against phospho-smad-3 (1:1000, cell 
signaling 9520); against collagen 1 (1:000, Rockland 600-401-103), fibronectin-1 (1:1000, 
abcam ab-2413) and β-actin (abcam).  
Before incubation with secondary antibodies, the membranes were washed. Washing steps 
with PBS-T for 5 times for 6 min followed by incubation with horse radish peroxidase (HRP)-
conjugated secondary antibody in 1% milk for 1h at room temperature. The following 
secondary antibodies were used: the anti-rabbit IgG-HRP (dilution factor of 1:3000, 7074P2 
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New England Biolabs), and the anti-mouse (dilution factor of 1:3000, NA931V GE 
Healthcare). ECL or Femto solutions A and B were mixed equally and applied to the 
membrane for 5 minutes to allow the detection of the signal via a chemiluminescence reaction, 
and the bands were visualized using Image Lab 5.1 software (Bio-Rad Laboratories). Signals 
were quantified and normalized to the signal of β-actin used as control. Statistical analysis and 
densitometry of the bands were done using Image Lab 5.1 software. 
 
3.4 Protease activity assay 
Protease activities were evaluated using Fluorescentresonance energy transfer (FRET) with 
specific FRET-substrates. The fluorescent substrates consist of a quencher molecule which 
physically interacts and interferes with a fluorescence molecule. Once the protease cleaves the 
substrate, the quencher is separated from the fluorescence molecule, andthis reaction produces 
a fluorescent signal which is detected from the plate reader. More active proteases are in the 
samples more fluorescence is released and detected over-time in a kinetic reaction. 
Reagents 
Table 11. FRET reaction buffer composition 
Ingredients 
50 mM Tris 
150 mM NaCl 
0.01% Triton X-100 
pH 5 
 
Table 12. FRET reaction solution for recombinant protein 
Component Volume 
Activity assay buffer 35µl 
Active Recombinant protein 10µl 
Substrate (100 µM) 5 µl 
Total 50 µl 
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Table 13. FRET reaction solution for sample 
 
Component Volume 
Activity assay buffer 35µl 
Sample 10µl 
Substrate (100 µM) 5 µl 
Total 50 µl 
 
FRET system was used in this study to quantify the enzymatic activity of CatB. To do so, the 
specific fluorogenic substrate of CatB Z-Arg-Arg-7-amido-4-methylcoumarin hydrochloride 
(50µM C429 Sigma Aldrich) was used. Serial dilutions of recombinant proteins were used in 
order to create a standard curve. The enzymatic activity of CatB was determined in BALF 
samples as well as cell culture medium. For the reaction, 96 well nunc-black plates were used 
and 10 µl of the sample of interest was added to the reaction buffer and incubated for 10 min 
at 37°C. The reaction was initiated by the addition of 10 µl of substrate into a final volume of 
50 µl of sample. The proteolytic activity was monitored by the appearance of 7-amino-4-
methylcoumarin (AMC) from the substrate by using Fluoroscan plate-reader at 450 nm for 60 
min. 
 
3.5 ELISA 
 
Cystatin C 
Cystatin C detection in human BALF was performed via an Enzyme-linked immunosorbent 
assay (ELISA) kit (R&D System DSCTC0). Same volume (50 l) of BALF samples was used. 
 
Pro-collagen 1a1 
Pro-collagen 1a1 detection in human BALF was performed via an Enzyme-linked 
immunosorbent assay (ELISA) kit (R&D Systems DY6220-05). Same volume (50 l) of 
BALF samples was used. 
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Active TGF-β1 detection 
Active TGF-β1 was detected in cell culture medium of RAW264.7 cells via an Enzyme-linked 
immunosorbent assay (ELISA) kit (Boster Mouse TGF Beta 1 ELISA Kit PicoKine™). Same 
volume (100 l) of medium was used. 1% of FBS supplemented medium was used as blank. 
 
3.6 Mouse experiments 
 
Mouse strains 
For this study, several mice strains were used. In the established mouse model of early stage 
of BOS HLA-A2–knock-in and C57BL/6J HLA were used; for functional studies Ctsb KO 
mice were used. Male B6, HLA (C57BL/6-Tg (HLA-A2.1)1Enge/J), and Ctsb–/– (B6;129-
Ctsbtm1Jde/J) mice were purchased from Jackson Laboratory.  
 
Study approval 
All human patients provided a written informed consent. The study was approved by the ethics 
committee of Ludwig-Maximilians University (333-10) and by the institutional ethics 
committee Comité de Protection des Personnes Ile-de-France VII, Le Kremlin-Bicêtre, France 
(protocol N8CO-08-003, ID RCB 2008-A00485-50). All mouse experiments were performed 
following the governmental and international guidelines and were approved by the local 
government of Upper Bavaria, Germany (project 55.2-1-54-2532.120.2015) and by the 
University of Colorado (protocol 115517(04)2D). 
 
Orthotopic left lung transplantation model 
Mice age was between 6-8 weeks at the time of the surgery. Orthotopic left lung 
transplantation (LTx) was performed as previously published (50). No immunosuppression 
was applied to recipient mice after the surgery but only 3 doses of pain killer. B6 and HLA 
mice were used as donors of left lungs; B6, and Ctsb -/- mice were used as recipients. Donor 
mice were anesthetized with an i.p. injection of ketamine/xylazine in saline solution. When all 
the reflexes were absent, the cardiopulmonary system was isolated and kept cold on ice during 
the preparation of the left donor graft. The pulmonary artery, bronchus, and pulmonary vein 
were separeted one by one, and then cuffed with, 24-, 20-, and 22-gauge cuffs, respectively. 
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The left lung was cut off from the heart and stored on ice for 1 hour before implantation. The 
recipient mouse was anesthetized with a reversible anesthetic, made of medetomidine (1 
mg/kg), midazolam (0.05 mg/kg), and fentanyl (0.02 mg/kg), also called MMF; then was 
intubated with a 20-gauge cannula and ventilated with a small-mouse ventilator (Harvard 
Apparatus), at a respiratory rate of 120 bpm and a tidal volume of 300 μl. The chest was incised 
on the left side between ribs 3 and 4, and the recipient left lung was carefully extracted with a 
clamp. The ventilation volume was reduced to 70 μl. Blood and air flow of the left lung were 
blocked with clamps. The hilar structure was carefully separated with blunted forceps.  The 
cuffed donor pipes were inserted into the recipient counterparts and fixed with 9-0 sutures. 
The recipient left lung was completely removed, and the chest was closed with a 6-0 suture, 
after removing all air bubbles from the chest. Antagonist was administrated under the skin, 
and the animal was extubated only when it showed signs of spontaneous breathing. After the 
surgery, the recipient mice were recovering in the cage to recover at 30°C overnight and 
received daily administration of buprenorphine for 3 days. Mice were sacrificed at specific 
time points. 
 
Left lung function measurement 
FlexiVent device was calibrated prior to each experiment, and individual mouse weight was 
inserted. Mice were anesthetized with MMF; when reflexes were absent, mice were intubated 
with a 20-gauge cannula, and connected to a mechanical ventilator at a frequency of 120 
breaths per minute and a volume of 300 μl. The chest was incised, and the right bronchus was 
clamped in order to measure the left lung function. The tidal volume was reduced to 70 µl. 
Afterwards, mice were removed from the mechanical ventilation, and their pulmonary 
function was analysed using the FlexiVent system. To mimic the lung volume during the 
natural breathing, mice were ventilated with a tidal volume of 3.5 ml/kg at a frequency of 150 
breaths/min. Lung mechanical properties, such as airway compliance, airway resistance, tissue 
elastance and inspiratory capacity were measured via Snap-Shot, Prime-8 and Quick-prime 
wave perturbations. Three readings per animal were measured for a reliable result. 
 
Bronchoalveolar lavage fluid collection (BALF) 
Right bronchus was clamped, while left lung was washed three times with 200 µl of cold 1x 
PBS (Gibco, Life Technologies) supplemented with a Cocktail of Protease Inhibitors (Roche 
Diagnostics). BAL was then separated into BALF (BAL fluid) and BAL cells via 
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centrifugation for 20 min at 400g at 4°C. Supernatants (BALF) were stored at -80 °C for 
protein detection. 
 
3.7 Lung tissue staining 
 
Lung tissue preparation 
Lungs were perfused via the pulmonary artery with cold 1x PBS to flush out the blood from 
the tissue and fixated with a 4% solution of paraformaldehyde for 24 h, before embedding. 
Lung lobes were cut into 3 mm pieces and embedded into liquid paraffin overnight. Paraffin 
blocks were cut via a microtome (Hyrax) into sections of 3 µm for further staining analysis. 
 
Deparaffinization 
Tissue sections were melted for 10 minutes at 65 °C, and paraffin was removed with baths of 
100% of xylene (twice), then 100%, 90%, 80% and 70% of ethanol, followed by running tap 
water for 5 min, and distilled water. Antigen retrieval was performed in a solution of 0.01 M 
citric acid (pH 6.0) in a cooker chamber for 30 minutes at 125°C, and for 10 minutes up to 
90°C. Tissue was rehydrated with PBS-Tween 20 (0,1%) for 10 min. 
 
Immunofluorescence staining 
Tissue was rehydrated for 10 min with 1x PBS-Tween-20 (0,01%), PBS-T, then blocked with 
3% BSA for 60 min, incubated overnight at 4 °C with primary antibodies. Tissue was washed 
for 3 times with PBST and incubated for 60 min at room temperature with secondary 
antibodies diluted in 3% BSA. For long storage, sections were embedded with Dako mounting 
medium (Agilent S3023). Images at defined magnifications were taken using AxioImager 
software with an M2 microscope (Zeiss), and processed with ImageJ. 
 
Immunohistochemistry (DAB) 
Tissue was rehydrated for 10 min with 1x PBS-Tween-20 (0,01%), PBS-T, while endogenous 
peroxidases were quenched by incubation in 3% H2O2 solution (30%, H1009, Sigma Aldrich) 
in 1x PBS for 10 min. Tissue was washed with PBS-T, and few drops of avidin solution 
(Avidin/Biotin Blocking Kit, SP-2001; Vector Laboratories) were added for 15 min, followed 
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by washing with PBS-T (1x PBS-Tween 20 0.1%); similarly, few drops of biotin solution were 
added for 15 min, washed with PBS-T; nonspecific antibody-binding sites were blocked with 
blocking solution consisting of 3% BSA in 1% PBS, PBSA for 1 h, and sections were 
incubated overnight at 4°C with the solution of primary antibody. After washing, the tissue 
was incubated with HRP-conjugated secondary antibody for 30 min at room temperature 
followed by the addition of the peroxidase substrate (ImmPACT DAB Peroxidase (HRP) 
Substrate, SK-4105; Vector Laboratories). After nuclear staining with Hematoxylin, 
dehydration and mounting, the sections were dried and scanned with Myrax scanner (Zeiss). 
 
Immunohistochemistry (Vulcan fast red) 
After deparaffinization, sections were rinsed with water, and quenched with a solution of 
H2O2 and methanol for 20 min, then washed for 3 times with 1x PBS; after antigen retrieval 
was completed, sections were washed for 3 times with washing buffer, blocked with 2 drops 
of Rodent Block M on each slide and incubated for 30 min at RT. Primary antibody solution 
was added on each slide and incubated overnight at 4°C. Samples were washed for 3 times, 
then incubated with AP Polymer from the secondary antibody for 15 min. After another 
washing step, 1 drop of Vulcan fast Red Chromogen solution was added on each slide and 
incubated up to 8 min. During the incubation, the staining was tracked overtime. Sections were 
washed again for 3 times, then rinsed in distilled water. Counter staining was performed with 
Hematoxylin solution up to 3 min followed by a fast washing in washing buffer, and the 
staining was fixed in 100% EtOH and Xylene. All the incubation steps were performed at RT. 
 
Hematoxylin eosin staining (HE) 
Tissue sections were stained with Hematoxylin (Hematoxylin solution, GHS-232, Sigma 
Aldrich) for 6 min, rinsed in distilled water, then washed under running tap water for 15 min, 
and again distilled water, then stained with eosin for 10 min and washed in tap water for 5 
min. Then, tissue was dehydrated twice with ethanol 100% and with xylene. Mounting was 
performed with Entellan glue (Merk). 
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Collagen staining 
Masson's trichrome is a three-colour staining protocol used for staining collagen fibers in 
tissue. This protocol produces red muscle fibers, blue collagen fibers, pink cytoplasm and 
proteins as well as dark purple cell nuclei. 
After deparaffinization, tissue sections were stained for 8 min with hematoxylin solution (for 
nuclear staining), washed with running tap water for 1 minute, then rinsed with distilled water. 
Sections were rinsed with a solution of Ethanol (70%) and HCl (0,1%), and washed for 5 min 
with running tap water, then incubated with Ponceau Fuchsin solution for 6 min, and quickly 
rinsed in tap water and distilled water. Sections were incubated for 1 min in Phosphomolybdic 
acid solution, then in Light Green solution for 5 min (extracellular matrix staining, since it 
binds collagen components). The staining was fixed with Ethanol 100% and Xylol. 
 
Signal Detection 
Images at different magnifications were acquired using AxioImager M2 microscope (Zeiss), 
AxioVision software (Zeiss), and scanner (Zeiss). 
 
3.8 Signal quantification 
 
Computer assisted stereology toolbox (CAST) 
Quantitative analysis of inflammation and collagen on samples previously stained for collagen 
was assessed by using the new computer assisted stereological toolbox (newCAST, 
Visiopharm) and an Olympus BX51 light microscope. 60 frames were randomly selected by 
the software with the x40 objective and defined by a line grid and points. The intercepts of 
lines with septal wall (I-septa), vessel wall (I-vessel), and airway wall (I-airway) and points 
localized on air space were counted and calculated Collagen/inflammatory cells = ∑Pair x L(p) 
/ ∑Isepta x 0.5, where L(p) is the line length per point. For each frame, inflammation and 
collagen were counted. CAST was also used for counting positive cells after Galectin 3 (Gal3) 
immunofluorescence staining. In order to quantify macrophages in mouse lung sections, 35 
random frames were selected by the software with the 40x objective, and positive cells for 
Gal3 were manually recorded for each frame. Recorded data were analysed via a statistical 
program, GraphPad v.8. 
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Image J 
Each single picture was analysed via ImageJ. A manual counting was used for the assessment 
of positive signal. An average of 20 random pictures for sample were considered for each 
analysis. 
 
3.9 Cell culture 
 
Cell lines 
Abelson murine leukemia virus transformed macrophage, RAW264.7, were used as an in vitro 
model of macrophages; mouse embryonic fibroblasts, MEF, were used as an in vitro model of 
fibroblast. RAW264.7 were cultured in DMEM/F12 medium, MEF in DMEM, media were 
supplemented with 10% FBS and 1% Pen/Strep, respectively. 
Cell seeding and stimulation 
RAW264.7 cells were seeded at 1,5x 105 in 12 well-plates. Cell pellet was used for protein 
and gene expression analysis; cell medium, also defined as “conditioned medium” (CM) was 
used for activity assay and mechanistic assays.  
For gene and protein expression analysis, RAW264.7 cells were seeded one day prior 
experiment, and they were stimulated with and without pre-incubation with a specific inhibitor 
of CatB (CA074, 10µM, Sigma C5732). Stimulation was performed by adding IFN-gamma 
(20ng/ml), LPS (1µg/ml), and IL4 (20ng/ml) to the medium, in a final volume of 1000µl per 
well for 6, 24, 48h. 
For mechanistic studies, RAW264.7 cells were seeded, then harvested for 18 hours with 1% 
FBS-supplemented medium; the day after they were pre-incubated with CA074 or DMSO and 
stimulated. Stimulation was performed adding IFN-gamma (20ng/ml), LPS (1µg/ml), and IL4 
(20ng/ml) to the medium, in a final volume of 500µl per well for 24h (as shown in Figure 8). 
Condition medium (CM) from RAW264.7, with and without CA074 and TGF-β1 receptor-2 
inhibitor (SB431542, 10 µM), was centrifuged at 300g at 4°C for 5 min in order to remove 
cell debris. 
CM was added to mouse embryonic fibroblasts, previously seeded at 5x105 cells in 6 well-
plates, and starved with 1% FBS-supplemented medium for 18 h. After 30 min, 
phosphorylation of SMAD3 protein (pSmad3) was assessed as marked of activation. 
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In this study negative technical controls (only medium), technical positive controls (2 ng/ml 
TGF-β1 recombinant protein), technical inhibitor controls (2 ng/ml TGF-β1 + SB431542, 10 
µM), and experimental controls were used. 
 
 
Figure 8. Schematic graph of mechanistic studies 
RAW264.7 are seeded in 12 well plates for 24h, and then stimulated with pro and anti-inflammatory cytokines 
for 6, 24 and 48 h. Cell lysate was used for gene expression analysis. Cell medium was used for activity assay, 
ELISA measurements, and for stimulation of fibroblasts 
 
3.10 Statistical analysis 
 
Data represent mean ± SEM. For the comparison between 2 groups, the statistical significance 
was assessed by a non-parametric t-test (Mann-Whitney); for the comparison between 3 and 
more groups, the difference was evaluated by one-way ANOVA followed by a post-test 
(Kruskal-Wallis) or by a Tukey’s multiple -test. Furthermore, the Stable group was compared 
to each BOS group via a non-parametric t-test (Mann-Whitney), since the group of Stable LTx 
patients is independent from BOS group. Median values are showed. Differences were 
considered to be statistically significant at P < 0.05. 
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4. RESULTS AND FIGURES 
 
4.1 Demographics of patients involved in the study 
 
Patients that underwent lung transplantation (LTx) were considered in this study and were 
classified as Stable LTx (S), if they were clinically stable during the entire study period (n=20), 
and as BOS (BOS), if they showed a significant decline of the lung function (n=22). Age, 
gender and the underlying lung disease of each patient were defined at the start of the study. 
All patients underwent double lung transplantation (DLTx), which, as previously mentioned, 
represents the most used approach because of the high rate of survival (15). Patients with BOS 
were monitored during the study, and BAL samples were collected, for most of patients, at 
different stages of the disease (Table 14). 
All BALFs that were used in this study were collected and stored from 2004 until 2014. For 
this analysis, patients with clear signs of BOS and Stable LTx patients were selected from our 
archive. All patients underwent double lung transplantation (DLTx) and were analyzed 
retrospectively. Pre-transplant underlying diseases were categorized into chronic obstructive 
pulmonary disease (COPD), interstitial lung disease (ILD), cystic fibrosis and pulmonary 
hypertension (PH). BOS was defined as a chronic decline in FEV1 by 20% from baseline FEV1 
(FEV 1 /FEV1 baseline <80%) that was present for a minimum of 3 weeks according to the 
current recommendations. Baseline FEV 1 (FEV1baseline) was defined as the mean of the two 
best measurements of FEV1 post-transplant, at least 3 weeks apart. Patients with BOS 
potentially caused by confounding conditions were excluded from the analysis. After lung 
transplantation during hospital stay and rehabilitation lung function analysis are performed 
weekly. After discharge, lung function tests are performed once per month for the first post-
surgery year and at least once every 3 months afterwards. LTx patients were followed up in 
our center and every lung function test was performed with a spirometry and body-
plethysmography. Since our samples were collected from a longitudinal study, we could 
classify as BOS-0, patients that were stable at the time of BAL collection, but developed later 
BOS-1 or higher. Stable LTx is a patient who has not developed CLAD for at least 5 years 
since the BAL sample was collected.  
 
 
 
 
 
 
 48 
Table 14. Demographics of lung transplanted patients from Munich cohort (cohort 1) 
Patients were clustered according to their gender, (F) for female and (M) for male, and according to the 
underlying diseases; COPD referred to chronic obstructive pulmonary disease, ILD/LF referred to interstitial 
lung diseases/lung fibrosis, CF referred to cystic fibrosis, and PH referred to pulmonary hypertension 
 
 Stable BOS 
Number of patients 20 22 
Age (years) 43 ± 8 47 ± 12 
Sex (F/M) 13 F/ 7M 8 F/ 14 M 
Underlying disease 
ILD 8 
COPD 2 
CF 6 
PH 4 
ILD/LF 11 
COPD 1 
CF 4 
PH 6 
Procedure (SLTx/DLTx) All DLTx All DLTx 
Days after LTx 669 ± 396 996 ±572 
Grade at BAL All 0 
BOS 0 n=20 (90%) 
BOS 1 n= 12 (54.5%) 
BOS 2 n=10 (45.5%) 
BOS 3 n=17 (77.3%) 
 
In order to diagnose a pathological state, LTx patients were clinically evaluated. Clinical 
evaluations were based on lung function parameters and lung imaging.  Along with the widely 
accepted definition of parameters that define BOS patients (JHLT Registry 2018), our cohort 
patients showed a significant decrease of the forced expiratory volume in the first second 
(FEV1%) (Figure 9A), while no change in total lung capacity TLC% was observed (Figure 
9B). These two parameters are crucial to distinguish BOS from RAS (107) (31) (104) (29). 
 
 A  
 
 B  
 
 
 
Figure 9. Lung function measurement 
of LTx patients 
(A) Analysis of the forced expiratory 
volume in 1 second decline (FEV1 %) in 
(S) and BOS patients; (B) Analysis of 
total lung capacity percentage (TLC %) 
in Stable (S) and BOS patients. Violin 
plot graphs show mean values +/- SD. 
Statistical significance was assessed 
using T-test student, Mann-Whitney U 
test (****P< 0.0001) (A, B) 
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Since macrophages are described to have a dual role in the lung immunology, BAL alveolar 
macrophage (MΦ) cell count was evaluated. Interestingly, we observed a remarkable decrease 
of the macrophage cell population at stage 2 of the disease, that recovered at the later stage of 
the disease BOS stage 3 (Figure 10).  Patients were solely selected according to the lung 
function analysis, and not according to the differential BAL count. Some of the Stable (S) 
patients had a low percentage number of macrophages, because of a temporary increase of 
neutrophils that was treated with Azithromycin. Stable patients remained clinically stable over 
a long period of time (>5 years).  
 
 
 
 
 
 
Figure 10. BAL alveolar macrophage cell count 
Quantification of alveolar macrophage percentage 
detected in BAL from Stable (S) and BOS patients, at 
different stages of the disease (Munich cohort). Violin 
plots show mean values. Statistical significance was 
assessed using via one-way ANOVA, Kruskal Wallis 
(**P< 0.005; ***P< 0.0003) 
Bronchoalveolar lavage (BAL) has been widely used to evaluate inflammatory biomarkers in 
the lung airways; moreover, the total protein content in BALF has been associated with the 
inflammatory response in the airways (108) (105). Therefore, BALF samples from Stable and 
BOS patients were analysed at different stages of the disease. No change in the protein content 
was found over the progression of the disease, neither between stable either in BOS patients 
(Figure 11). 
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Figure 11. Total protein concentration in BALF of 
LTx patients 
Analysis of the total protein concentration in BALF 
from Stable (S) and BOS patients (BOS), at different 
stages of the disease (Munich cohort). Violin plots show 
mean values. Statistical significance was assessed using 
one-way ANOVA, Kruskal Wallis 
 
Due to the lack of lung tissue from this Munich cohort at the time of BALF collection as well 
as at the later stage of the disease, a second human cohort of LTx patients (France cohort) was 
considered. Unfortunately, lung tissue sampling was achieved only from the advanced stage 
of the disease (BOS-3). Lung sections were obtained by excision of explanted grafts from LTx 
patients before re-transplantation (re-LTx) and embedded in paraffin for tissue analysis. Age, 
gender, underlying disease, type of surgery and post-surgery complications were defined for 
each patient at the time of the lung tissue collection (Table 15).  
Moreover, the human control sections used for histology were derived from healthy parts of 
lungs from non-transplanted donors, Healthy donors (HD). 
 
Table 15. Demographics of lung transplanted patients from France cohort (cohort 2) 
Underlying 
disease 
LTx type Age, Sex 
Rejection 
grade 
Therapy Complications 
Time 
before 
reLTx 
PAH 
Heart-
lung 
31, F All stage 3 Immunosuppressive 
Aspergillus aereus 
 
 
PAH 
histiocitosis 
SLTx 42, F  Immunosuppressive 
Edema 
Staphylococcus 
aereus 
Infection 
 
IPD DLTx 41, F  Immunosuppressive 
 
Aspergillus aereus 
Fibrotic 
pneumopathy 
7 years 
Not known 
Heart-
lung 
F  Immunosuppressive  6 years 
 
PAH 
 
 
41, F 
 
 
Immunosuppressive 
 
Infection 
 
2 years 
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4.2 Newly formed collagen levels increased in BOS patients 
 
Patients that developed BOS are characterized by marked tissue collagen deposition that 
negatively affects long-term functional outcomes after LTx (107-108). Pro-collagen 1a1 is a 
component of a procollagen 1 molecule, and it is a well-described marker of fibroblast 
activation during lung fibrosis (109). COL1A1 gene encodes pro-collagen a1 chain, which 
combined with another pro-collagen a1 chain and with a pro-collagen a2 chain build up a 
molecule of Pro-collagen 1. Pro-collagen 1 molecules are processed in the extracellular space, 
where they organize into long and thin fibrils that cross-link around cells in a mature form 
(collagen 1), which is following responsible for the lung tissue fibrosis. The levels of soluble 
pro-collagen 1a1 were assessed in the BALF of LTx patients using an enzyme-linked 
immunosorbent assay. When comparing BOS LTx patients with Stable (S) patients, a large 
increase of newly formed pro-collagen 1a1 was found in BALF from BOS patients (7.4 fold-
change, P= 0.0003) (Figure 12A). Pro-collagen-1a1 levels were already high at stage-1 of the 
disease (655.02 pg/ml in BOS-1 vs 98.8 pg/ml in S, P= 0.0009), and stage-2 of the disease 
(425.31 pg/ml in BOS-2 vs 98.8 pg/ml in S, P=0.029), and peaked at stage-3 (1081.74 pg/ml 
in BOS-3 vs 98.8 in S, P= 0.0048) when compared with Stable LTx patients (Figure 12B). No 
significant differences were found between the BOS groups after using a Mixed effects model 
analysis followed by a Tukey’s multiple comparisons test. 
 
Figure 12. Newly formed pro-collagen 1A1 levels increased at early stage of BOS disease 
(A, B) Quantification via ELISA of secreted pro-collagen 1a1 in bronchoalveolar lavage fluid (BALF), from 
Stable (S), and from BOS patients (BOS). Bar graphs show mean values +/- SD. Statistical significance was 
assessed using Mann-Whitney U test (***P< 0.0003) (A), and one-way ANOVA, Kruskal Wallis (*P< 0.05; **P< 
0.005) (B) 
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Most importantly, pro-collagen 1a1 levels negatively correlated with FEV1% values after LTx 
(P= 0.0018) (Figure 13). These results suggest that fibroblast activation during BOS 
development occurs at early stages of the disease.  
 
Figure 13. Newly formed collagen secretion correlated with the pulmonary function 
Linear correlation between pro-collagen 1a1 secreted in BALF and FEV1 % of Stable and BOS patients; BOS0 
patients are excluded for the analysis because of no change in FEV1% from the baseline. The different stages of 
the disease are highlighted using a colour code that stays consistent in all figures of this study: green for Stable 
patients (S), purple for BOS patients at stage 1 of the disease; orange for BOS patients at stage 2 of the disease, 
and purple for BOS patients at stage 3 of the disease 
 
4.3 Cystatin C levels decreased in BOS patients 
 
Previous studies have shown Cystatin-C (CysC), an endogenous regulator of the activity of 
several cathepsins, was able to prevent activation and proliferation of fibroblasts in injured 
lung tissue and in cancer cells (86-87). Therefore, CysC levels were assessed in explanted 
human lung tissue by immunostaining. Lung tissue from BOS stage-3 patients (cohort 2, Table 
15) showed a remarkable decrease in CysC expression (35.3 positive cells/20 FOV in H, vs 
14.3 positive cells/20 FOV in BOS-3, P= 0,011) (Figure 14A-B) compared to Healthy donors 
(HD) patients, and mainly localized in macrophages using Galectin-3 staining as macrophages 
marker (Figure 15).  
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Figure 14. CysC protein expression decreased in BOS lung tissue 
(A) Representative immunofluorescence staining of Cystatin-C (CysC), in red, in human lung tissue, from Healthy 
donors (HD) and BOS stage-3 patients (scale bar of 50µm); (B) Quantification of CysC-positive cells in 20 fields 
of view (FOV) in human lung tissue. Violin plots show mean values +/- SD. Statistical significance was assessed 
using Mann-Whitney U test (*P< 0.05) 
 
 
 
Figure 15. CysC expression in macrophages in the lung tissue of Healthy donors 
Representative immunofluorescence staining of Cystatin-C (CysC) in lung tissue of Healthy donor patients 
(scale bar of 50µm). Nuclear staining (in blue), Gal3 macrophage staining (green), and CysC staining (red) 
 
4.4 Cathepsin B activity increased in BOS patients 
 
Cathepsin B (CatB) activity was reported to be involved in tissue fibrosis (83-84). We 
hypothesized that the activity of CatB in BALF from BOS patients was dysregulated as a 
consequence of decreased levels of CysC. CatB activity in BALF of LTx patients (cohort 1) 
was measured by using a FRET-based activity assay. BALF from BOS patients were compared 
to Stable patients. A substantial increase of CatB activity was observed in BOS patients (21.3 
ng/ml in BOS vs 3.05 ng/ml in H, P= 0.0001) (Figure 16A), (16.9 ng/ml in BOS-0 vs 2.69 
ng/ml in S, P<0.0001) compared to Stable LTx patients (Figure 16B). Moreover, similarly 
with pro-collagen levels, CatB activity also negatively correlated with FEV1% values from 
DAPI Gal3 CysC merged
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baselines after BOS development already at early stage of the disease, indicating that CatB 
maybe contribute to the disease progression (P= 0.014) (Figure 17). 
 
Figure 16. CatB activity increased in BOS 
(A, B) Quantification of Cathepsin-B (CatB) activity in human BALF via a FRET-probe based activity assay 
adding 10μM of Z-Arg-Arg-AMC substrate to the reaction buffer. CatB concentration was measured with serial 
dilutions of CatB recombinant protein. Bar graphs show mean values +/- SD. Statistical significance was 
assessed using Mann-Whitney U test (****P< 0.0001) (A), and one-way ANOVA, Kruskal Wallis (*P< 0.05; 
**P< 0.005; ***P< 0.0003; ****P< 0.0001) (B) 
 
 
Figure 17. The increase of CatB 
activity was associated with a poor 
lung function 
Linear correlation between pro-
collagen 1a1 secreted in BALF and 
FEV1 % of Stable and BOS patients; 
BOS0 patients are excluded for the 
analysis because of no change in FEV1% 
decline. The different stages of the 
disease are highlighted using a colour 
code that stays consistent in all figures 
of this study: green for Stable patients 
(S), purple for BOS patients at stage 1 of 
the disease; orange for BOS patients at 
stage 2 of the disease, and purple for 
BOS patients at stage 3 of the disease 
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4.5 Cathepsin B expression increased in BOS patients 
 
Since the presence of active Cathepsin B depends on different post-translational mechanisms 
(96), it was investigated whether also the translation of CatB was regulated during BOS 
development after LTx. Remarkably, total CatB protein level was significantly increased in 
BALF from BOS patients (4.5 fold change, P< 0.005), as well as the pro-form of CatB (pro-
CatB) (2.7 fold change, P< 0.05), and the mature form of CatB (mature CatB) (2 fold change, 
P< 0.05) compared to Stable patients ( Figure 18A-B). 
A 
 
B 
 
Figure 18. CatB protein expression increased in BOS 
(A) Representative Western blots of human BALF samples from Stable and BOS patients. (B) Quantification of 
protein levels of total CatB, pro-CatB and mature CatB determined and quantified according to the molecular 
weight. Bar graphs hows mean values +/- SD. Statistical significance was assessed using T-student test, Mann-
Whitney U test (*P< 0.05; **P< 0.005) (B) 
 
Similarly, the localization and expression of CatB in explanted lung tissue from BOS stage-3 
patients (cohort 2, Table 15) showed a marked increase of CatB expression when compared 
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with Stable LTx patients (Figure 19 upper panel). Interestingly, we observed a significant 
increase of collagen deposition in areas of CatB localization (as showed in Figure 19 lower 
panel). 
 
Figure 19. CatB protein expression increased in lung tissue of BOS patients 
Paraffin-embedded lung tissue was obtained from Healthy donors and from BOS stage-3 patients and from stable 
LTx patients. Representative immunostaining of CatB expression in human lung tissue (upper panel) (scale bar 
of 100µm); Representative staining of collagen deposition in human lung tissue (lower panel) (scale bar of 
100µm) via Masson Trichrome staining (MTC) 
 
The presence of causality between CatB activity and pro-collagen 1a1 levels over the 
progression of BOS was evaluated, Interestingly, a synergistic increase of CatB activity 
together with the secretion of pro-collagen 1a1 was observed along BOS development (Figure 
20). Taken together, these results indicate that CatB can trigger the collagen biosynthesis, 
which plays a key role in the progression of BOS. 
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Figure 20. CatB and pro-collagen 
secretion increased over the progression of 
BOS 
Evaluation of CatB and pro-collagen 1a1 
expression over BOS progression (+/- SEM). 
Dotted line represents the activity of CatB 
(ng/ml), and continuous line represents the 
protein level of procollagen 1a1 (pg/ml). 
CatB activity and procollagen 1a1 levels were 
measured in BALF collected from LTx 
patients. The different stages of the disease 
are highlighted using a colour code that stays 
consistent in all figures of this study: green for 
Stable patients (S), purple for BOS patients at 
stage 1 of the disease; orange for BOS 
patients at stage 2 of the disease, and purple 
for BOS patients at stage 3 of the disease 
 
4.6 Enhanced Cathepsin B activity in IPF patients 
 
In this study, BALF samples were analysed from LTx patients with a different history of 
underlying disease (Table 14). We questioned whether the history of pulmonary disease, 
before LTx, was affecting the activity of CatB during BOS development. Interestingly, this 
investigation revealed a substantial increase of CatB activity in patients previously diagnosed 
for lung fibrosis (LF/IPF) (53.9 ng/ml in BOS vs 7.3 ng/ml in H, P= 0.0047) (Figure 21A), 
rather than for other diseases (Figure 21B). Remarkably, BOS patients diagnosed for LF 
showed decreased CysC levels in BALF samples compared with LF patients without signs of 
rejection (23.3 ng/ml in BOS vs 81.57 ng/ml in H, P= 0.0048) (Figure 21C), but not in other 
underlying diseases (Figure 21D).  
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Figure 21. CatB activity and CysC levels are impaired in patients with lung fibrosis 
Analysis of CatB activity and CysC levels accordining to the underlying diseases. (A) Quantification of CatB 
activity via a FRET-probe based activity assay in BALF from patients who were affected by lung fibrosis (LF); 
(B) and in patients affected by other underlying diseases (cystic fibrosis, CF, and pulmonary hypertension, 
PH);(C) Quantification of CysC levels via ELISA in BALF from patients who were affected by lung fibrosis (LF); 
(D) and in patients affected by other underlying diseases (cystic fibrosis, CF, and pulmonary hypertension, PH). 
Violin plots show mean values. Statistical significance was assessed using Mann-Whitney U test (**P<0.005) 
(A, C), and one-way ANOVA (B, D). 
 
 
4.7 Infiltrating macrophages are the main source of CatB in BOS 
 
The localization of CatB have been investigated by immunohistochemistry. One hallmark of 
BOS is the influx of immune cells into the allograft lung, and particularly mononuclear cells 
such as T and B cells as well as macrophages were showed increased in areas surrounding 
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airways and vessels (30). Specifically, macrophages, stained here for Gal3, have been shown 
to express CatB in the lung tissue of patients with BOS (Figure 22). 
 
Figure 22. Macrophages were the main source of CatB in lung tissue of BOS patients 
Representative immunofluorescence staining of cathepsin B (in red), and of macrophage marker, Galectin 3 (in 
green) in human lung tissue from Healthy donors and BOS stage-3 patients (scale bar of 50 µm) 
 
In addition, CatB expression was investigated in lung tissue from our previously established 
mouse model of LTx (52), comparing syngeneic mice (B6→B6) with a model of early stage 
of BOS (HLA→B6), 2 months after LTx. Similar to human LTx lungs, alveolar macrophages 
were identified as the main source of CatB, in areas surrounding the airways and vessels 
(Figure 23). 
 
 
Figure 23. Macrophages were the main source of CatB in lung tissue of the mouse model of BOS 
Left lungs from B6, and HLA mice were orthotopically transplanted into B6 mice and analysed 2 months after 
LTx (B6→B6 n= 4, HLA→B6 n= 4). Representative immunofluorescence staining for CatB (red) and for 
macrophage marker, Gal3 (green) (scale bar of 50 µm) in murine lung tissue 
 
Furthermore, to understand whether CatB-macrophages were recruited or donor-specific, left 
lung tissue from HLA→B6 mice was stained for HLA.A2, which is only expressed on the 
surface of donor cells, and for CatB. Interestingly, only recipient-derived macrophages, that 
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were negative for HLA.A2, expressed CatB. This finding suggests that recipient monocyte-
derived macrophages are the main source of CatB (Figure 24). 
 
 
Figure 24. Macrophages expressing CatB were recipient-derived 
Representative immunofluorescence staining for cathepsin-B (in green) and left lung donor-derived antigen, 
HLA.A2 (red) in lung tissue from HLA→ B6, 2 months after LTx.  
 
Furthermore, quantitative analysis of macrophages cell number by immunofluorescence 
staining of lung tissue from LTx mice revealed a significant increase of macrophages cell 
number (324 macrophages/FOV in BOS mice vs 97 macrophages/FOV in Ctrl mice; P= 
0.0079) (Figure 25A) as well as CatB-positive cells (110 CatB positive cells/FOV in BOS 
mice, vs 5 CatB positive cells/FOV in Ctrl mice; P= 0.04) (Figure 25B) in HLA→B6 mice 
compared to B6→B6 control mice.  
 
A 
             Galectin 3 
 
B 
                   Cathepsin B 
 
 
Figure 25. Macrophages and CatB-
positive cells increased in BOS 
(A) Quantification of Galectin-3 positive 
cells in 20 randomly selected fields of view 
(FOV); (B) Quantification of CatB 
positive cells in 20 randomly selected 
fields of view. Values were normalized to 
the total area. Violin plots show mean 
values. Statistical significance was 
assessed using Mann-Whitney U test (*P< 
0.05; **P< 0.005) 
 
In strong agreement with our findings, recent single cell RNA seq-analysis from two 
independent research groups have confirmed macrophages as the predominant source of CatB 
in lungs from lung fibrosis patients before LTx. Of relevance, CatB expression was highly 
expressed in macrophages deriving from fibrotic areas of explanted lungs of patients affected 
by idiopathic pulmonary fibrosis (as shown in Figure 26A-B). 
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Figure 26.  Macrophages were the main source of CatB in lung fibrosis patients 
(A) Combined t-distributed stochastic neighbour embedding (t-SNE) analysis of single-cell transcriptomes from 
three normal (control), three idiopathic pulmonary fibrosis (IPF) patients (110) and (B) from 10 non-fibrotic 
control and 20 PF lungs. Analysis of 114,396 cells identified 31 distinct cell types. single-cell suspensions from 
peripheral lung tissue removed at the time of lung transplant surgery from patients with IPF (n=12) and no 
fibrotic control (n=10) (111). Cathepsin-B (labelled as CTSB) gene expression in immune cells in IPF patients 
compared with controls 
 
 
Beside macrophages, T and B cells were described to infiltrate allograft lung tissue already at 
early stage of the rejection (51), while alveolar neutrophils have been indicated as BOS 
predictors, and as biomarkers of BOS progression (45). Therefore, the expression of CatB was 
investigated in T, B cells as well as in neutrophils using immunofluorescence staining and 
specific marker for each cell population. Interestingly, only few neutrophils showed a slight 
localization of CatB in the mouse model of LB (Figure 27A), wheares T and B cells were 
negative for CatB (Figure 27B). 
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Figure 27. CatB was slightly expressed in neutrophils 
Left lungs from HLA mice were orthotopically transplanted into B6mice and analysed 2 months after LTx (n= 
4). (A) Representative immunofluorescence staining of CatB (red), and neutrophils, Ly6G-positive (green) in 
lung tissue (scale bar of 50 µm); (B) Representative immunofluorescence staining of CatB (red), and T-cell 
marker, stained for CD3 (green) (upper panel), and B-cell marker, stained for CD45R (green) in murine BOS 
lung tissue (lower panel) 
 
4.8 Cathepsin B expression increases in a murine model of LB 
 
Since human BOS patients and our mouse model of LB showed a marked increase of CatB 
expression in BALF and lung tissue, respectively, the contribution of CatB during the 
progression of the disease was investigated, in a time-dependent manner, in the orthotopic 
mouse model of LTx. Here, for the first time, we provided a comprehensive understanding of 
BOS pathogenesis on the cellular and molecular level, by using lung tissue and BALF samples 
at different stages of the disease. 
Left lungs from wildtype mice (B6) and HLA-A2–knock-in (HLA) mice were orthotopically 
transplanted into B6 recipient mice and analysed at days 7, 14, and 28 after LTx (Figure 28).  
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Figure 28. Experimental design of the orthotopic mouse lung transplantation model 
Experimental design of a time-course orthotopic murine left lung transplantation (LTx) model. Left lungs from 
B6 and HLA were orthotopically transplanted into B6 mice and sacrificed at day 7, 14, and 28 after LTx.  Lung 
tissue and BALF were analysed over time 
 
In order to evaluate the progression of the disease, left lung tissue from B6→B6 and HLA→B6 
mice were stained and quantified for collagen and inflammation in a time-dependent manner. 
Left lung tissue from mice reminiscent of human BOS showed a time-dependent increase of 
peribronchiolar and perivascular inflammation together with a progressive peribronchiolar 
fibrosis (Figure 29A-B).  
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Figure 29. Inflammation and fibrosis started at early stage of BOS development 
(A) Representative pictures of murine left lung tissue stained for inflammation and for collagen by using Masson 
trichrome staining protocol (scale bar of 200µm); (B) Quantification of collagen and inflammation of (A) was 
performed via a computer-assisted stereology analysis (CAST). Values are represented as mean value and 
expressed as volume on surface (µm3/µm2) 
 
To determine the expression of CatB over the progression of the disease, left lung tissue from 
the mouse model of LB was stained for CatB by immunofluorescence in a time-dependent 
manner. Consistent with human data (Figure 14B) an increase of CatB expression at 14 days 
post-LTx was detected in lung tissue and BALF of LB mice already after 14 days post-LTx 
(Figure 30, 31A and B). 
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Figure 30. CatB expression increased during BOS progression 
Representative immunofluorescence staining of CatB (red) in areas surrounding airways and vessel in lung 
tissue of a mouse model of BOS (scale bar of 50 µm) 
 
Since CatB expression is positively associated with collagen deposition, we investigated the 
expression of collagen-1 and fibronectin-1, two ECM components, in lung tissue and BALF 
over the progression of the disease. Remarkably, the expression of collagen-1 increased in LB 
lung tissue after 14 days post LTx (Figure 31A). Fibronectin-1 (FN1), which is needed for the 
assembly of the collagen matrix and shown to play an important role in fibrosis (112), was 
also increased after 14 days post LTx in BOS mice (Figure 31A-B). 
 
 
Figure 31. Extracellular matrix proteins and CatB increased during BOS progression 
(A) Representative Western blots of Cathepsin-B, collagen 1 and fibronectin 1 (FN1) expression in murine lung 
tissue lysates from B6→B6 and HLA→B6 at different time points; (B) and in BALF. Equal amount of total protein 
was loaded for lung tissue analysis (15 µg), and equal volume was loaded for BALF analysis. Pro-forms and 
mature forms of Cathepsin-B were detected according to the molecular weight 
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4.9 Genetic deletion of Cathepsin-B protected lungs from BOS 
development 
 
To elucidate whether CatB plays a role in the development of BOS, HLA.A2/B6 left lungs 
were transplanted into B6 or Ctsb-/- recipient mice, and lung function, tissue inflammation and 
collagen deposition after 28 days were analysed (Figure 32). 
 
 
Figure 32. Experimental design of the orthotopic mouse LTx model for functional studies 
Experimental design of orthotopic left lung transplantation (LTx) in mice. CatB knock-out mice (Ctsb-/-) were 
used as recipient of HLA.A2 left lungs and were compared with wild-type B6 recipients. Mice were sacrificed 28 
days after LTx, to analyse lung function, lung tissue inflammation and fibrosis 
 
First, similar to human patients, the lung function of recipient mice was evaluated at day 28 
post-LTx. CatB-deficient mice demonstrated improved lung compliance (0.017 ml/cmH2O in 
Ctsb-/- mice, vs 0.0069 ml/cmH2O in BOS mice; P= 0.011), as well as a higher inspiratory lung 
capacity (0.31 ml in Ctsb-/- mice, vs 0.13 ml in BOS mice) in comparison to LB mice (Figure 
33A-B). Furthermore, Ctsb-/- mice were protected from enhanced airway resistance (1.5 
cmH2O/ml in Ctsb
-/- mice, vs 9.39 cmH2O/ml in BOS mice, P= 0.029), and tissue elastance 
(57.55 ml/cmH2O in Ctsb
-/- mice, vs 124.6 ml/cmH2O in BOS mice, P= 0.026) (Figure 33C-
D), indicating that CatB participated in BOS pathogenesis.  
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Figure 33. CatB deficient mice were protected from lung dysfunction 
In vivo measurements of left lung function via Flexivent, 28 days after LTx. At least three measurements for each 
parameter were recorded. Measurements were normalized to the body weight of the recipient mouse. Violin plots 
show mean values +/- SD. Statistical significance was assessed using one-way ANOVA, Kruskal Wallis (*P< 
0.05; **P< 0.005) 
 
In order to investigate whether the observed protective effect on lung function depends on 
reduced collagen accumulation, lung tissue sections were evaluated for collagen expression 
and inflammation. In agreement with the improvement of the lung function, left lungs from 
Ctsb-/- showed mild signs of fibrosis in peribronchial areas and all over the lung tissue (Figure 
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34A), compared to the BOS mice. Importantly, Ctsb-/- mice revealed reduced septal 
inflammation and fibrosis (Figure 34B). Strikingly, genetic deletion of CatB in recipient mice 
efficiently protected the transplanted graft from BOS progression. 
A 
 
 
B 
 
Figure 34. CatB deficient mice were protected from lung fibrosis 
(A) Representative pictures of collagen and inflammation are shown for each group (1000µm, left panel; 100 
µm, right panel); (B) Quantification of inflammation and collagen of left lung tissue, in areas surrounding 
airways, vessel and septum, was performed via computer-assisted stereology (CAST). Violin plots show mean 
values +/- SD. Statistical significance was assessed using one-way ANOVA, Kruskal Wallis (*P< 0.05; **P< 
0.005) 
 
However, genetic deletion of CatB did not affect macrophage infiltration into the lung (Figure 
33). Taken together, these data demonstrate that, in our mouse model of LB, the release of 
CatB rather than macrophages number induced BOS development. 
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Figure 35. Genetic deletion of CatB did not affect macrophage infiltration 
Quantification of macrophage cell number in left lung tissue at 28 days after LTx via computer-assisted 
stereology (CAST). (A) Representative immunofluorescence staining of Gal3, marker for macrophages (green) 
in lung tissue of LTx mice (scale bar of 50 µm). (B) Quantification of Gal3-positive cells (A). Violin plots 
represent mean values. Statistical significance was assessed using Mann-Whitney U test 
 
4.10 Cathepsin B expression in pro-inflammatory macrophages 
 
CatB-positive macrophages significantly increased in areas affected by fibrosis. To further 
investigate the molecular function of CatB, we stimulated macrophage cell lines towards a 
pro-inflammatory, M1 phenotype, with IFN- and LPS, or anti-inflammatory, M2 phenotype, 
with IL4 (Figure 36). Unstimulated macrophages, M0, were used as control. Interestingly, the 
in vitro study showed that only M1 macrophages experienced a marked increase of CatB 
mRNA after 24h of IFN- and LPS stimulation (Figure 37A); similarly, also the activity of 
CatB was found notably increased in the medium of M1 macrophages (Figure 37B).  
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Figure 36. Experimental design of the in vitro model of BOS 
Experimental design of macrophage (Raw264.7) polarization with IFN-γ (20 ng/ml), LPS (1 µg/ml), IL-4 (20 
ng/ml) and medium alone. Macrophage cell supernatant was used to analyse CatB activity, active TGFβ1 levels, 
and for further treatment of fibroblasts (MEF) 
 
 
Figure 37. CatB expression and activity increased in inflammatory M1 macrophages 
Macrophage cell lysate was used for gene expression analysis; (A) Gene expression analysis of murine Ctsb in 
macrophages under different stimulations and time points; (B) Quantification of CatB activity in macrophage 
cell supernatant via a FRET-probe based activity assay. Violin plots represent mean values +/- SD. Statistical 
significance was assessed using one-way ANOVA, Kruskal Wallis (B, C) (*P< 0.05; **P< 0.005; ****P< 
0.0001) 
 
Since the in vitro study showed that pro-inflammatory macrophages were the source of CatB, 
the expression of CatB was further addressed in the lung tissue of the mouse model of LB by 
immunofluorescence. Left lung tissue from HLA→B6 mice was stained for NOS2, a marker 
of pro-inflammatory macrophages, and for CD206, a marker of anti-inflammatory 
macrophages, together with CatB. Strikingly, CatB expression was found, similar to the in 
vitro analysis, localized in pro-inflammatory M1 macrophages (Figure 38A-B). 
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Figure 38. CatB was expressed in pro-inflammatory macrophages in the mouse model of BOS 
(A) Representative immunofluorescence staining of CatB (green) and of M1 macrophages marker, NOS2 (red) 
(scale bar of 50 µm), and (B) of CatB (red) and M2 macrophages marker, CD206 (green) expression in the left 
lung of the murine model of BOS (scale bar of 10 µm)  
 
4.11 Cathepsin-B contributed to fibroblast activation via TGFβ1-
maturation 
 
Pro-inflammatory M1 macrophage-derived cytokines (TNF-, IL1-) were previously shown 
to be highly released into the BALF of BOS patients (113).  
Since macrophages were shown to be an important source of TGF-β1 in lung (111), the gene 
expression of tgfb1 under different stimulation conditions was analysed in the in vitro model. 
A significant increase of tgfb1 gene expression was confirmed in M1 polarized macrophages, 
but not in other macrophages (Figure 39). 
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Figure 39. TGF-β1 expression increased 
in M1 macrophages 
Gene expression analysis of murine tgfb1 
in macrophages at different times of 
differentiation. Violin plots show mean 
values +/- SD. Statistical significance was 
assessed using one-way ANOVA, Kruskal 
Wallis (*P< 0.05; ****P< 0.0001) 
 
To perform mechanistic studies, the effect of a specific CatB inhibitor (CA074) on CatB’s 
activity was evaluated in the cell medium of M1 macrophages at different time points. CA074 
successfully inhibited the activity of CatB in the cell medium up to 48h (Figure 40A). Next, 
we addressed the question whether CatB was regulating the maturation of latent free TGF-β1 
(pro-TGF-β1) released from M1 macrophages. Interestingly, pre-treatment of M1 
macrophages with CA074 resulted in the inhibition of pro-TGF-β1 processing (Figure 40B). 
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Figure 40. TGF-β1 maturation was affected by CatB inhibitor 
(A) Quantification of CatB activity via a FRET-based activity assay and (B) Quantification of active TGFβ1 via 
ELISA in cell supernatant of macrophage-pretreated with CA074 (10µM), or DMSO, and stimulated for 24h and 
48h with IFN-γ (20 ng/ml) and LPS (1 µg/ml). Violin plots show mean values +/- SD. Statistical significance was 
assessed using one-way ANOVA, Kruskal Wallis (A, B, C) and Turkey´s multiple test (D-E) (*P< 0.05; **P< 
0.005; ***P< 0.0003) 
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To further validate the regulation of CatB-induced fibrosis, fibroblasts were treated with 
macrophage-derived cell medium. Since the phosphorylation of SMAD3 (pSMAD3) proteins 
is the main marker of the canonical TGF-β1 signaling pathway activation, and promotes the 
transcription of ECM proteins, the signal of pSMAD3 after fibroblasts treatment was 
evaluated. Cell medium from stimulated M1 macrophages and unstimulated macrophages, 
with and without CatB and TGF-β1 receptor inhibitor, was used to stimulate fibroblasts for 30 
minutes. The phosphorylation of pSMAD3 was analysed in fibroblast cell lysate by western 
blotting. Strikingly, fibroblasts showed a significant increase in TGF-β1-dependent activation 
after being stimulated with M1-derived cell medium, which was specifically mediated by CatB 
(Figure 41). Taken all together, our data demonstrate that M1 macrophages secrete CatB and 
by that cause the TGF-β1-mediated activation of fibroblasts. 
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Figure 41. CatB promoted fibroblast activation 
Quantification of phosphorylated SMAD3 (pSMAD3) signal in MEF cells after 30 minutes of stimulation with 
macrophage-conditioned medium (CM). Macrophages were pre-treated with CA074 (10µM) or DMSO for 1h, 
then stimulated for 24h with IFN-γ (20 ng/ml) and LPS (1 µg/ml). Internal controls were collected from 
unstimulated macrophages, and the experimental controls were collected from stimulated macrophages that were 
subsequentially treated with SB431542 (10µM). Cell supernatant was collected, centrifuged and added to starved 
fibroblasts (n=2, in 3 independent experiments). Western blot signals were normalized to β-actin, and internal 
controls. Violin plots represent mean values +/- SD. Statistical significance was assessed using one-way ANOVA, 
Turkey´s multiple test (*P< 0.05; **P< 0.005; ***P< 0.0003) 
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5. DISCUSSION  
 
Several cellular and molecular markers of BOS have been described, in particular, the 
increased number of macrophages, neutrophils and lymphocytes (51), as well as soluble 
mediators (47). However, little is known about the fibro-proliferative mechanism and potential 
triggers that promote this process in areas surrounding airways.  
The aim of this doctoral thesis was to investigate potential targets and mechanisms involved 
in the development of the BOS disease. 
Cathepsin B (CatB) is a cysteine protease with unique properties. Contrary to other proteases, 
CatB is able to act as exopeptidase as well as endopeptidase, and exerts its activity under acidic 
and neutral pH conditions (102). Its enzymatic activity is broad, targeting highly similar 
substrates, preferentially in cleavage sites after basic and hydrophobic residues (114).  
However, the contribution of CatB in the BOS development has not yet been investigated, we 
therefore aimed to determine the functional role of CatB in BOS development. 
Our study brought to our knowledge that 1) CatB activity and expression are increased in BOS 
patients; 2) and that negatively associated with the lung function; 3) pro-inflammatory and 
recipient-derived macrophages were the main source of CatB; 4) CatB release resulted in a 
TGF-β1-dependent activation of peri-bronchiolar collagen production.  
The lack of knowledge about BOS development in human patients depends on several factors. 
One of the major reasons for this scientific gap is the limitation of human samples for research 
as well as the lack of a reproducible mouse model of BOS combined with the technical 
challenges of murine LTx. Translational studies are restricted to the usage of bronchoalveolar 
lavage fluid (BALF) and peripheral blood of LTx patients. Reliable lung tissue sampling is 
mainly available from patients that have already reached a very late stage of the disease, 
rendering it hard to investigate early-events for predictive studies. In this project, we 
performed a longitudinal study. BALF samples were stored longitudinally in the research 
bioarchive and then retrospectively selected for this study. In total, 22 BOS patients, and 
BALFs available at different BOS stages were selected and compared to 20 Stable LTx 
patients who did not develop BOS-related symptoms for at least 5 years after BALF collection 
(Table 14). BOS stages and relative BALF samples were grouped according to the % decline 
in FEV1 values: they were grouped in BOS-0 patients that were stable at the time of BAL 
collection, but developed later BOS-1 or higher; in BOS-1 when the FEV1 value was between  
66-80%; in BOS-2 when the FEV1 value was between 51-65%; and in BOS-3 when the FEV1 
value was ≤50% (Table 1) (23, 28). Patients with infection as cause for lung function decline 
were not included in the study. Acute cellular rejection>A1 was not present in any of BOS 
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samples at the time of BAL collection. Lung tissue sections were obtained from BOS stage-3 
patients, from a second human cohort (Table 15). This, coupled with our mouse lung 
transplantation model (52) that simulates the early stages of BOS development, enabled us to 
identify potential drivers of the disease that enter in play at very early stage. 
We demonstrated a substantial increase of CatB activity in the BALF of BOS patients, 
starting already at BOS stage-0 (Figure 16). In accordance with our finding, a previous study 
showed a marked increase of CatB activity in BALF samples of mice, during the early phase 
of bleomycin-induced fibrosis, prompting the involvement of CatB in lung fibrosis (94). 
Importantly, the expression of CatB increased over the disease progression in BOS patients as 
well as in our mouse model of BOS (Figure 28, 29). This observation is comparable to 
previous studies performed in samples from patients and mice suffering from advanced liver 
fibrosis (5). 
We then investigated the main source of CatB in BOS lung tissue. In cancer, CatB 
expression was demonstrated in infiltrating macrophages within metastatic areas, and its 
activity was crucial for tumor invasiveness, suggesting CatB as key-player in lung tumor 
progression (115). Interestingly, we showed that CatB expression was primarily found in pro-
inflammatory recipient-derived macrophages in areas affected by marked signs of fibrosis and 
inflammation in BOS patients as well as in mice (Figure 22-24). We could further confirm in 
vitro that CatB-producing macrophages were predominantly pro-inflammatory M1 
macrophages (Figure 38). 
Previous studies have shown that the lung tissue of patients with BOS is characterized 
by a marked mononuclear infiltration in the areas surrounding the distal airways, together with 
a dense accumulation of collagen (116). However, histological information is widely reported 
at the latest stage of the disease (BOS stage 3) but not at earlier stages. Although, surveillance 
bronchoscopy, including BAL and transbronchial biopsy (TBB), is also part of the routine 
follow up in several centers, as well as in ours, lung tissue collected by TBB is not routinely 
stored in the research bio-archive, but only used for diagnosis purposes. Therefore, we were 
not able to directly compare BALF and TBB over the progression of BOS disease. In this study 
we used tissue sections that were obtained from the stage-3 of the disease, when lungs are 
explanted from BOS patients before re-LTx (116). The most relevant finding in our study is 
the observation of significant changes in disease-related factors in a time-dependent manner 
in our mouse model of BOS (Figure 34). Furthermore, we showed a time-dependent increase 
of newly formed collagen in BALF from BOS patients, that was increasing already at early 
stage of the disease (Figure 12), and negatively affected the pulmonary function of LTx 
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patients (Figure 13). Similarly, CatB activity was negatively correlated with the lung function 
after LTx (Figure 17).  
The premature increase of CatB activity in the BALF (Figure 16B) suggested its 
contribution in promoting the biosynthesis of collagen. The increased levels of pro-collagen 
1a1 were already reported by Keane et al. as a result of fibroproliferation of alveolar epithelial 
cells (117), as well as by King et al. in the BALF of patients with interstitial lung disease (118). 
Importantly, we showed that the increase of CatB activity occurred already at a very early 
stage of the disease (BOS-0), and later the production of collagen started (BOS-1), suggesting 
CatB as a potential trigger of the incessant production of collagen in BOS development. This 
observation is of particular importance since CatB and collagen levels in BALF could 
potentially be used in the future as simple and fast detectable biomarkers for earlier diagnosis 
of BOS.  
Another very strikingly finding was that CatB-deficient mice showed a reduced peri-
bronchial collagen production and graft protection against the development of BOS (Figure 
32-34). However, the lack of CatB did not affect the recruitment of macrophages into the 
allograft (Figure 35), proposing CatB as player in the BOS development. With our mouse 
model of LTx, we could definitively demonstrate that the exclusive lack of CatB was sufficient 
to prevent collagen deposition and BOS development. 
Due to the extensive immunosuppressive therapy, impaired mucous-clearance and 
continuous exposure to external microbes, BOS patients have shown high incidence of 
bacterial infection before and/or during the progression of the disease, that has been associated 
with an increased release of inflammatory mediators, such as LPS (120) and IFNγ (121-122).  
In our study, to simulate the in vivo mechanism, we therefore used LPS and IFNγ as main 
triggers for pro-inflammatory macrophages (Figure 36) (123).  
In order to address the role of CatB in the development of the BOS disease, we 
simulated the in vivo mechanism of chronic rejection by using an in vitro system (Figure 36). 
Macrophages were used as source of CatB, while fibroblasts were used as effector cells and 
source of collagen. Importantly, we demonstrated that pro-inflammatory macrophages were 
the main source of CatB in the in vitro as well as in the in vivo model of rejection (Figure 
37A-38). Furthermore, using a specific inhibitor of CatB-activity, called CA074, we displayed 
that CatB, once released in the extracellular space, binds TGF-β1 and converts it into its active 
form (Figure 40) to promote fibroblasts activation (Figure 41). Although there is no clear 
knowledge about the physical interaction between CatB and TGF-β1, we speculate that CatB 
preferentially binds TGF-β1 on the Arginine-residuals (100) of the cleavage site, and by that 
promotes the dissociation of the latent protein (LAP) from the active sequence of TGF-β1. 
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This finding already suggests CatB inhibition as a promising therapeutic target in the treatment 
of BOS. However, we have to take into account that other factors (85) might play a role in the 
development of BOS progression. 
The autocrine effect of CatB in TGF-β1 driven activation of fibroblasts was previously 
reported in in vitro studies (103). Fibroblasts from IPF patients showed higher levels and 
activity of CatB when compared with healthy patients; moreover, CatB activity enhanced the 
activation of TGF-β signalling and by that promoted the production of collagen in IPF patients 
(103). 
By addressing the role of macrophage-derived CatB in BOS, we demonstrated that the 
paracrine signalling of CatB was necessary to activate latent TGF-β1. Interestingly, a previous 
study confirmed the ability of pro-inflammatory M1 macrophages in inducing fibroblast 
activation; although, the key mediator was not investigated (119).  
In-depth analysis of CatB activity revealed a marked increase in BOS patients with a 
history of pulmonary fibrosis (Figure 21A), and not in other underlying diseases (Figure 
21B). We believe there is a systemic bioavailability of CatB in those patients, which depends 
on the pro-inflammatory macrophages that are recruited into the allograft after LTx. In 
accordance with our findings, recent single cell-transcriptome analysis, from two independent 
groups, showed a substantial increase of CatB levels in lungs that were explanted from patients 
with lung fibrosis (Figure 26). Consistently, we observed in the same group of patients with 
BOS a concomitant reduction in CysC (Figure 21C), and not in other underlying diseases 
(Figure 21D). Therefore, we think that the increase of CatB activity in BALF from LTx 
patients with underlying lung fibrosis results from the lack of the negative regulation from its 
endogenous regulator (CysC). Interestingly, previous findings demonstrated the presence of 
lung fibrosis as consequence of CysC deficiency (88). 
According to the findings achieved in the present study, and in the light of the increasing 
demand of personalized medicine, we here suggest the usage of a CatB inhibitor for BOS 
patients with a history of lung fibrosis, although is not yet investigated in clinical studies.  
On the preclinical level, several chemical inhibitors of CatB activity have been 
described. CatB inhibition is widely investigated in the context of tumor, since it is strongly 
suggested as driving factor of tumor progression in several solid organs (124-125), as well as 
in the lung (126). Commercially available and newly synthesized drugs have been tested in 
vitro and in vivo models. Among these, Ca074, has been described as a specific inhibitor of 
CatB activity also in a preclinical study, preventing tissue fibrosis in rat (127).  
Moreover, a recent study has developed new construct that conjugated a CatB inhibitor to a 
liposomal nanocarrier (LNC-NS-629), which is able to target extracellular and intracellular 
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CatB in an irreversible way. Moreover, this drug was showed to efficiently reach macrophages 
and inhibit its target (128). Based on all our findings, we suggest this compound as a potential 
therapy for LTx patients to prevent BOS progression; for instance, by using a drug liposome 
aerosol-based system to specifically target the lung, we could use lower concentration of the 
drug, prevent local irritation, increase the bioavailability of the drug and increase potency with 
reduced systemic toxicity. This approach would improve the efficiency of therapeutic 
approaches (129). 
In this work, we successfully obtained a reasonable number of BALF samples from 
LTx patients, most of those referring to a different stage of BOS disease (Table 14), giving 
the opportunity of investigating disease-related targets along the progression of the disease; 
however, we were limited from the heterogeneity of LTx patients. The BALF Munich cohort 
was mainly composed of patients with a history of lung fibrosis. In order to strengthen our 
findings for clinical application, a larger number of cases (around 10) per underlying disease 
is preferred, in order to obtain results that are clinically useful. Moreover, the use of a second 
human cohort is suggested in order to estimate whether different therapeutic strategies affect 
our findings. 
In conclusion, based on our results, in human as well as in mice, this study clearly shows the 
crucial role of macrophage-produced CatB in the TGFβ-1 mediated production of collagen by 
fibroblasts already at early stages of BOS, suggesting CatB as early marker of BOS 
progression. 
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